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 INTRODUCTION  
 
Microorganisms are among the most ancient forms of life. Their diverse characteristics 
have allowed a phylogenetic classification into different groups based on genome 
sequence comparison. Each group displays distinctive biochemical and structural 
features as well as a great capacity of adaptation to the most diverse and changing 
environmental conditions, e.g. pH fluctuations, temperature variations, salinity, dryness, 
etc. (1). A general classification based on salt tolerance capacity has been proposed (2). 
According to this classification, some bacterial genera comprise species that hold the 
capacity to live in both marine and terrestrial environments. These organisms are 
deemed halotolerant. Meanwhile, those unable to survive under ocean conditions have 
been classified as terrestrial. The ones requiring salinity in order to survive are 
considered halophilic. The present work focuses on bacteria able to live in the marine 
habitat; some of them, halophilic. The distinctive feature of this kind of bacteria is their 
strict need for salt in order to grow and thrive in nature. The main objectives of this work 
are two: 1) to understand the ecological implications of marine bacteria especially in 
regard to the production of secondary metabolites, 2) to investigate the profit that can be 
made out of these chemical tools within the context of research on behalf of public health 
improvement. Subjects of our research are marine-derived myxobacteria, members of 
the proteobacterial group and Labrenzia sp. strain 011 (Ostsee6), member of the -
proteobacteria group; lastly, other bacteria retrieved from marine environments. 
1.1. Classification of bacteria  
In order to illustrate bacterial taxonomy and timescale localization, Figure 1-1 shows 
different bacterial groups and the approximate time of appearance as well as the 
estimated evolutionary point in time whereby the capacity to adapt from marine to 
terrestrial environments was acquired (3). 
Introduction  
2 
 
 
Figure 1-1 The illustration taken from (3) shows the approximate points of appearance 
of the different bacterial groups in the course of evolution. The black lines represent 
bacterial classes. Thicker lines are lineages that include hyperthermophilic species. The 
group with the number of species comprised is shown in the panel on the right side, and 
the time scale in billions of years ago is presented below. The arrows represent 
geological relevant phenomena. 
 
Special emphasis will be put on group II of Figure 1-1, where the more relevant bacterial 
classes for the purposes of this work, namely proteobacteria, and proteobacteria 
are clustered. According to the Figure 1-1, these groups of bacteria shared a common 
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ancestor about 3 million year ago (3). However, many members of these groups display 
either autotrophic or heterotrophic behavior (4, 1). In order to fulfill their nutritional 
demands, heterotrophic bacteria often require products of secondary metabolism to 
weaken or kill their preys and also to secure their habitats (5). These products play 
important roles in the way these organisms interact in their habitats.   
Concerning classification based on salt-tolerance, it remains unclear whether some 
bacteria lost their capacity to live in marine ecosystems or developed salt-tolerance in 
the course of evolution, this way becoming apt for dwelling in sea-like conditions.  
1.2. Microbial interactions in the marine environment 
1.2.1. Ecological implications of secondary metabolites from marine 
microorganisms 
The marine environment comprises a series of biotic and abiotic entities, whose 
coexistence is governed and balanced by different interactions. Mostly, interactions of 
macroscopic organisms are illustrated by predation and mutualism (6); small-scale 
interactions often involve microscopic organisms displaying, among others, parasitic or 
symbiotic relations with other microorganisms, algae and marine fauna (7–10). On this 
level of existence, it is often observed that chemical substances derived from secondary 
metabolism mediate these interactions. Examples of these are the bacteriocins, 
antibacterial proteinaceous compounds produced by bacteria, which probably act as 
anti-competitor agents in terrestrial and marine habitats (11). Interestingly, many of these 
substances may also be capable to exert biological effects in the clinical context (12). 
One example of this is the broad spectrum lantibiotic subtilomycin, produced by the 
marine sponge-associated bacterium Bacillus subtilis strain MMA7 (Figure 1-2) (13). This 
compound has shown growth inhibition of various Gram-positive and Gram-negative 
bacteria (13).   
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Figure 1-2 Subilomycin as presented by (13) is a marine derived lantipeptide that 
presents a broad range of antibacterial activity against Gram-positive and Gram-negative 
organisms (13). It also shows antifungal activity on strains of Candida albicans 
pathogenic to humans (13). This compound was isolated from the bacterium Bacillus 
subtillis MMA7 associated with marine sponges (13). 
 
1.2.2. Marine microorganisms as potential producers of novel bioactive 
substances of clinical interest 
Surely, the following question arises: why is it worthwhile to invest time and efforts in 
marine organisms? The answer is that compared to terrestrial environments, scientists 
have only marginally explored marine habitats in search for novel drugs or improvement 
of the current arsenal of available drugs. From this fact, an inference can be made 
considering the large number of terrestrial-derived compounds active per se or acting as 
scaffolds for synthetic modifications: the odds of finding structural novelty, and thus novel 
activities are much higher in marine organisms than in terrestrial ones (14–17).  
This notion is supported by numerous works appointing substances of marine origin as 
potential candidates to become lead compounds and enter the drug market (18–20). 
Especially, efforts have been directed to anticancer drug testing (20). Examples of 
marine-derived compounds in medical use are scarce, but those undergoing clinical trials 
are numerous and promising (21, 20, 22).  Table 1-1 shows the clinical status of some 
compounds isolated from marine environments and their putative producer or the 
organism from which the compounds were isolated. However, the true producer of the 
compounds remains in many cases unknown.  
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Table 1-1 This pipeline published by (21) presents the current perspective of relevant 
marine-derived substances and their clinical status. The information shown in the table 
corresponds to the status of the compounds in 2017. The reference provides a 
supplement, which is constantly updated and is available online.   
 
Clinical 
status 
 
Compound 
name 
 
Marine 
organism 
 
Chemical class 
 
Disease area 
FDA-
Approved 
 
Cytarabine 
Vidarabine 
Ziconotide 
Trabectedin 
Eribulin Mesylate 
Brentuximab 
 
 
Sponge 
Sponge 
Cone snail 
Tunicate 
Sponge 
Mollusk/ 
Cyanobacterium 
 
Nucleoside 
Nucleoside 
Peptide 
Alkaloid 
Macrolide 
Antibody 
conjugate 
 
Cancer 
Antiviral 
Pain 
Cancer 
Cancer 
Cancer 
 
Phase III 
Plinabulin  
Plitidepsin 
Glembatumumab  
 
Fungus  
Tunicate 
Mollusk/ 
Cyanobacterium 
 
Diketopyperazine  
Depsipeptide 
Antibody 
conjugate 
Cancer 
Cancer  
Cancer   
Phase II 
DMXBA 
Polatuzumab  
Pinatuzumab 
Lifastuzumab 
AGS-16C3F 
Denintuzumab  
Depatuxizumab 
All structures 
were isolated 
from 
Mollusk/ 
cyanobacterium 
associations 
All structures are 
antibody 
conjugates 
All structures have 
been investigated as 
anticancer drugs  
 
Lurbinectedin  
 
Tunicate  
 
Alkaloid 
 
Cancer  
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It is often thought that bacteria associated with macroscopic organisms produce the 
bioactive compounds (23). In some cases, it was indeed shown that microorganisms are 
responsible for the biosynthesis of active compounds (18, 24). This idea was recently 
illustrated by findings involving a strain of the marine bacterium Labrenzia sp. PHM005 
(25). This marine sponge-associated microorganism was found to be the producer of a 
pederin-like substance with cytotoxic and antiviral capacities (Figure 1-3). These 
observations find further support in the insights gained through genomic mining 
experiments, which constantly reveal the biosynthetic potential encoded in bacterial 
genomes (26–28). Additionally, experiments involving sponge metagenomic sequencing 
revealed the bacterial origin of pederin-like molecules in sponges (29). 
GTS 21 Worm  Alkaloid  Neurologic disorders  
Phase I 
Tisotumab 
Enfortumab  
MLN-0264 
SGN-LIV1A 
ASG-15ME 
ASG-67E 
ABBV-838 
ABBV-221 
ABBV-399 
ABBV-085 
GSK2857916 
All structures 
were isolated 
from 
Mollusk/ 
cyanobacterium 
associations  
All structures are 
antibody 
conjugates  
 
All structures have 
been investigated as 
anticancer drugs  
 
 
 
Bryostatin  
Marizomib  
PM060184 
 
Bryozoan 
Bacterium  
Sponge  
 
Macrolide  
Lactone  
Polyketide  
 
All structures have 
been investigated as 
anticancer drugs 
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A)   Pederin                                               B) Pederin-like compound 
 
Figure 1-3  A) The structure of the antiviral and cytotoxic compound pederin is presented 
according to (30). Pederin was initially thought to be produced by the beetle Paederus 
sabaeus, but nowadays it is accepted that its endosymbiotic bacteria produce this 
compound and also bioactive derivatives thereof (31). B) The pederin-like compound 
modified from (25) is produced by the halophilic bacterium Labrenzia sp PHM005 and 
has shown cytotoxic activity against four different human cell lines: A549 (ATCC CCL-
185) (lung carcinoma); HT-29 (ATCC HTB-38) (colon adenocarcinoma); MDA-MB-231 
(ATCC HTB-26) (breast adenocarcinoma); and PSN-1 (ATCC CRL-3211) (pancreas 
adenocarcinoma). 
 
This example proves that in silico explorations are a helpful tool for the isolation of 
compounds, and prediction of potential production of molecules, and their chemical 
nature. Further advantages of this approach were demonstrated through the isolation of 
the antimicrobial compound foxicin A (see Figure 1-4), which is produced by the 
terrestrial bacterium Streptomyces diastatochromogenes strain Tü6028 (32).  
 
      
 
 
Figure 1-4 The terrestrial-derived antimicrobial compound foxicin A A) as presented by 
(32) and the marine-derived antitumor haliamide B) as presented by (33). These 
molecules represent results of successful in silico screening for biosynthetic genes with 
subsequent isolation of bioactive compounds.   
A) Foxicin A 
B) Haliamide 
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Additional examples of these strategies are provided elsewhere (34, 35). Concerning 
marine-derived bacteria, in silico and chemical screening of the metabolome of the 
myxobacterium Haliangium ochraceum SP1 lead to the structural elucidation of 
haliamide (see Figure 1-4), a promising antitumor compound (33). Within this context, 
marine-derived myxobacteria represent a fruitful research topic concerning natural 
products. Recent works provide information yielded by experiments conducted in silico 
on genomes of marine myxobacteria, whereby gene clusters of putative secondary 
metabolites of diverse chemical nature, e.g. terpenes, polyketides, non-ribosomal 
peptides and hybrids thereof were detected (36).  
1.3. Clinical applications of secondary metabolites: tackling antibiotic 
resistance. 
Antibiotic resistance is one of the adaptation skills developed by pathogenic 
microorganisms. This phenomenon emerged almost simultaneously with the first 
prescription of antibiotics to treat infections about 80 years ago (37). Figure 1-5 illustrates 
the breakthrough of new drugs over time and the emergence of their first resistant 
bacterial pathogen (38).  
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Figure 1-5 This timeline modified from Ventola et al (38) depicts clearly the constant 
appearance of antibiotic resistance along with the discovery and application of novel 
drugs. According to the author (38), penicillin was in limited use prior to widespread 
population usage in 1943.  
 
Interestingly, Figure 1-5 shows that bacterial pathogens often require less than 10 years 
to undermine the efficacy of treatments, posing serious threats to human life and 
consequently to the public healthcare providers worldwide. Even the latest defensive 
lines, i.e damptomycin and ceftaroline have been overthrown. This is a heavy burden 
considering that multidrug-resistant pathogens develop infections usually in hospitalized 
patients with preexisting conditions, adding up to the severity of their ailments and thus 
to the cost of the medical care. Barriere and  McGowan’s  publications provide deeper 
details regarding the economic implications of antibiotic resistance (39, 40).  
In light of the global growing concern about antibiotic resistance, the potential and 
applications of marine-derived compounds in antimicrobial therapy are one of the main 
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goals in the field of modern natural product research. Thus, it is urgent to find novel 
structures to overcome, at least for some time, the resistance of pathogens.  
The aforementioned premise, highlighting the structural novelty of marine-derived 
compounds, allows us to think that the ocean could provide efficient antimicrobials with 
novel mechanisms of action against pathogenic targets, which have successfully 
developed resistance to the drugs in use hitherto. 
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 SCOPE OF THE PROJECT 
 
The marine environment is a source of chemical compounds with unprecedented 
structures and probably, novel or improved biological effects within the context of clinical 
applications. 
This work consists of investigations on marine-derived bacteria. The research conducted 
comprehends in silico genomic explorations of myxobacteria in order to evaluate their 
potential as producers of bioactive molecules.  
Furthermore, bacterial isolates available in our group were investigated in their capacity 
to produce chemical substances of biological interest. From these investigations, two 
structurally unusual lipidic structures were obtained and were assessed as antimicrobial 
agents. Additionally, their possible role in inflammatory phenomena was investigated. 
As a parallel objective, through the assessment of biological activities of the compounds 
isolated, it was intended to understand the ecological function of their microbial 
producers in the marine environment.    
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 MATERIALS AND METHODS 
 
3.1. Materials 
3.1.1. Chemicals and solvents  
Table 3-1 List of chemicals utilized for general procedures.  
Chemicals Manufacturer 
Acetone ----- 
Acetone – d Deutero GmbH (Kastellaum, Germany) 
Acetonitrile VWR International GmbH (Darmstadt, Germany) 
Agar ----- 
Boric acid Roth Chemie (Karlsruhe, Germany) 
CaCl2 x 2H2O Merck KgaA (Darmstadt, Germany) 
Chloroform – d Deutero GmbH (Kastellaum, Germany) 
DCM Dichloromethane 
DMSO Roth Chemie (Darmstadt, Germany) 
dNTPs Promega GmbH (Mannheim, Germany) 
Ethanol 99.8 p.a. Roth Chemie (Karlsruhe, Germany) 
Ethidium bromide Roth Chemie (Karslruhe, Germany) 
Ethyl acetate  --- 
Gel loading dye (6x) Fermentas GmbH (St. Leon Rot, Germany) 
Isopropanol Roth Chemie GmbH (Karlsruhe, Germany) 
Methanol  --- 
Methanol – d Deutero GmbH (Kastellaum, Germany) 
MgCl2 x 6H2O Merck KGaA (Darmstadt, Germany) 
NaOH Merck KGaA (Darmstadt, Germany) 
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peqGOLD Agarose PEQLAB Biotecnologie GmbH (Erlangen, Germany) 
Phosphoric acid Roth Chemie (Karlsruhe, Germany) 
Sepabeads 207 Supelco (USA) 
Silica gel 60 Merck KgaA (Darmstadt, Germany) 
 
Organic solvents such as chloroform, dichloromethane, ethyl acetate, acetone, and 
methanol were distilled prior to use. Water for HPLC and molecular biology assays was 
obtained from a Milli-Q Water Purify. 
3.1.2. Antimicrobials  
Table 3-2 List of antimicrobials employed for different purposes in this work. 
Substance Manufacturer 
Ampicillin Roth Chemie GmbH (Karlsruhe, Germany) 
Streptomycin Sigma Aldrich Co. LLC (St. Louis, MO, USA) 
Miconazole Sigma Aldrich Co. LLC (St. Louis, MO, USA) 
Cycloheximide ≥96 % Roth Chemie GmbH (Karlsruhe, Germany) 
 
Ampicillin was necessary for the transformation of E. coli competent cells in LB-ampi 
medium. Additionally, was used as positive control in disc diffusion tests, as well as 
streptomycin and miconazole. Cycloheximide was needed to suppress fungal growth in 
WCX agar plates for isolation of bacteria.  
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3.1.3. Enzymes 
Table 3-3 Enzymes used in molecular biology for cloning purposes. 
Enzyme Manufacturer 
GoTaq Flexi DNA polymerase Promega (Mannheim, Germany) 
Proteinase K Roth (Karlsruhe, Germany) 
Restriction enzymes Fermentas GmbH (St. Leon-Rot, Germany) 
RNase (DNase free) Promega (Mannheim, Germany) 
T4DNA ligase Fermentas GmbH (St. Leon-Rot, Germany) 
 
3.1.4. Kits, standards and buffers 
Table 3-4 Kits used in molecular biology for cloning purposes. 
Article Manufacturer 
Gene rulerTM DNA ladder mix 
Fermentas GmbH (St. Leon-Rot, 
Germany ) 
PureYieldTM Plasmid Miniprep System Promega (Mannheim, Germany) 
QIAprep Spin Miniprep Kit Quiagen GmbH (Hilden, Germany) 
QIAquick Gel Extraction Kit Quiagen GmbH (Hilden, Germany) 
QIAquick PCR purification Kit Quiagen GmbH (Hilden, Germany) 
TBE (10x) 
0.89 M Tris base, 0.02 M EDTA, 0.87 M 
boric acid, pH 8.3 
Wizard SV Gel and PCR Clean-Up 
System 
Promega (Mannheim, Germany) 
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3.1.5. Culture media and related dissolutions   
Table 3-5  Media for cultivation and isolation of bacteria and complementary substances 
utilized are listed. 
Name Constituents and proportions 
Artificial sea water 100% 
0.1 g KBr, 23.48 g NaCl, 10.61g MgCl2 6H2O, 1.47 g 
CaCl2 2H2O, 0.66 KCl, 0.04 g SrCl2 6H2O, 3.92 g 
Na2SO4, 0.19 g NaHCO3, 0.03 g H3BO3, 1 L distilled 
water 
ASW-WCX  
15 g agar in 1 L ASW (75%); after autoclaving 1 mL 
vitamin B12, 1 mL trace element solution, 2 mL 
cycloheximide 
Casitone broth  
Casitone pancreatic digest of casein 1.0 g BD Bacto™ 
225930, 100 mL distilled water, pH 7.5 
CY/ASW 
3.0 g casiton, 1.0 g yeast extract in 1 L artificial sea 
water, pH 7.2; after autoclaving add 1 ml filter sterilized 
trace element solution and 1 ml vitamin B12 solution (0.5 
mg/ml) 
CY/ASW agar 
3.0 g casiton, 1.0 g yeast extract in 1 L artificial sea 
water, 15 g agar, pH 7.2; after autoclaving add 1 ml filter 
sterilized trace element solution and 1 ml vitamin B12 
solution (0.5 mg/ml) 
Halophilic    Bacteria that require sea-like salinity conditions to grow 
Halotolerant 
Bacteria able to grow in presence of sea-like salinity 
conditions as well as in the absence of salt 
LB - ampicillin medium 
10 g tryptone, 5 g yeast extract, 10 g NaCl in 1 L of 
water, pH 7.5; after autoclaving 1 mL of ampicillin 100 
Materials and methods  
16 
 
mg/mL are added. 15 g/L were added to produce solid 
medium. 
LB agar 
10 g tryptone, 5 g yeast extract, 5 g NaCl, 15 g Agar, in 1 
L of water, pH 7.5 
LB medium 
10 g tryptone, 5 g yeast extract, 10 g NaCl in 1 L of 
water, pH 7.5 
Marine agar 
Bacto peptone 5.00 g, Yeast extract 1.00 g, Fe(III) citrate 
0.10 g, NaCl 19.45 g, Na2CO3 0.16 g, Na2SO4 3.24 g, 
CaCl2 1.80 g, MgCl2 8.80 g, KCl 0.55 g, KBr 0.08 g, SrCl2 
34.00 mg 
H3BO3 22.00 mg, Na-silicate 4.00 mg 
NaF 2.40 mg, (NH4)NO3 1.60 mg, Na2HPO4 8.00 mg, 1 L 
distilled water, 15 g agar, pH 7.5 
Marine broth Difco 2216 
Bacto peptone 5.00 g, Yeast extract 1.00 g, Fe(III) citrate 
0.10 g, NaCl 19.45 g, Na2CO3 0.16 g, NaSO4 3.24 g, 
CaCl2 1.80 g, MgCl2 8.80 g, KCl 0.55 g, KBr 0.08 g, SrCl2 
34.00 mg 
H3BO3 22.00 mg, Na-silicate 4.00 mg 
NaF 2.40 mg, (NH4)NO3 1.60 mg, Na2HPO4 8.00 mg, 1 L 
distilled water, pH 7.5 
SOC broth 
20 g trypton, 5 g yeast extract, 0.5 g NaCl, 2.5 mL 1 M 
KCl, 1 L distilled water; after autoclaving 20 mL glucose 1 
M 
Trace element solution 
20 mg ZnCl2, 100 mg MnCl2 x 4H2O, 10 mg boric acid, 
10 mg CuSO4, 20 mg CoCl2, 5 mg SnCl2 x 2H2O, 5 mg 
LiCl, 20 mg KBr, 20 mg KI, 10 mg Na2MoO4 x 2H2O and 
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5.2 g Na2-EDTA x 2H2Oin 1 L of water. The solution was 
sterilized by filtration. 
VY/2 
50 ml sterilized baker’s yeast suspension (10%), 1.36 g 
CaCl2 x 2 H2O, in 1 L of water, pH 7.2; after autoclaving 
add 1 ml filter sterilized vitamin B12 solution (0.5 mg/ml) 
VY/4-ASW 
25 mL sterilized baker’s yeast suspension, 375 mL 
artificial sea water 200%, in 600 mL distilled water (75%), 
pH 7.5; after autoclaving 1 ml filter sterilized trace 
element solution and 1 ml vitamin B12 solution (0.5 
mg/ml) 
 
3.1.6. Microorganisms   
Table 3-6 Fungi and bacteria used as test strains for DDT are shown. The table includes 
microorganisms used for genomic mining and bacteria isolated during the present work, 
as well as the competent E. coli cells used for cloning. 
Organism Source 
Arthrobacter crystallopoietes DSM 20117 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Bacillus megaterium DSM32 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Bacillus subtilis 168 MiBi collection 
Candida albicans I-11134 MiBi collection 
Candida albicans I-11301 MiBi collection 
Citrobacter freundii I-11090 MiBi collection 
Corynebacterium xerosis Va167198 MiBi collection 
Echerichia coli I-11276b MiBi collection 
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Echerichia coli O-19592 MiBi collection 
Enhygromyxa salina DSM 15201 NCBI GenBank 
Enterococcus faecium I-11054 MiBi collection 
Enterococcus faecium I-11305b MiBi collection 
Escherichia coli DSM498 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Eurotium rubrum DSM 62631 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Haliangium ochraceum DSM 14365 NCBI GenBank 
Klebsiella pneumoniae subsp. ozeanae I-
10910 
MiBi collection 
KNS I-10925 MiBi collection 
Labrenzia alba CECT5094 Colección Española de Cultivos Tipo 
Labrenzia alba CECT5095T Colección Española de Cultivos Tipo 
Labrenzia alba CECT5096 Colección Española de Cultivos Tipo 
Labrenzia alba CECT7551 Colección Española de Cultivos Tipo 
Labrenzia sp. strain 011 (Ostsee6) This study 
Listeria welchimeri DSM 20650 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Lysobacter sp This study 
Microbotryum violaceum MB#110229 MiBi collection 
Micrococcus luteus ATCC 4698 MiBi collection 
MRSA LT-1334 MiBi collection 
MRSA LT-1338 MiBi collection 
MRSE LT-1324 MiBi collection 
MSSA 5185 MiBi collection 
MSSA I-11574 MiBi collection 
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Mycobacterium smegmatis ATCC 70084 MiBi collection 
Mycotypha microspora MB#271115 MiBi collection 
Nannocystis exedens ATCC 25963 NCBI GenBank 
Plesiocystis pacifica SIR 1 NCBI GenBank 
Pseudomonas aeruginosa I-10968 MiBi collection 
Pseudoroseovarius crassostreae DSM 16950 
Deutsche Sammlung von 
Mikroorganismen und Zellkulturen 
Saccharomyces cerevisiae MiBi collection 
Staphylococcus aureus 133 MiBi collection 
Staphylococcus aureus SG 511 MiBi collection 
Staphylococcus simulans 22 MiBi collection 
Stenotrophomonas maltophilia I-10717 MiBi collection 
Stenotrophomonas maltophilia O-16451 MiBi collection 
Unknown bacterium called Siel 3 This study 
Unknown bacterium called Siel 4 This study 
XL1-Blue E. coli cells Stratagene (La Jolla, CA, USA) 
 
3.1.7. Vectors 
Table 3-7 Here are shown the cloning vector used for 16S rDNA fragments during 
bacterial identification 
Vector Resistance Manufacturer 
pGEM-T easy Ampicillin 
Promega (Mannheim, 
Germany) 
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3.1.8. Cell cultures 
Table 3-8 Embryonic kidney cells were used for cytotoxic assays 
Cell type Source 
HEK293 ACC 305 embryonic kidney 
cell line 
Deutsche Sammlung von Mikroorganismen 
und Zellkulturen 
 
3.1.9. Primers  
Primers used in this study were purchased from Eurofins MWG Operon (Ebersberg, 
Germany). After the reception, the oligonucleotides were dissolved in nuclease-free 
water to a concentration of 100 pmol/μl and stored at -20°C. 
Table 3-9 Classic pair of primers pA/pH employed for identification of bacterial isolates 
Primer Sequence (5’ to 3’) Purpose 
pA 
pH 
AGAGTTTGATCCTGGCTCAG 
AAGGAGGTGATCCAGCCGCA 
Identification of bacteria 
based on 16S rDNA 
 
3.1.10. Software and databases 
The bioinformatic analyses in this work were carried out mainly on NCBI platforms for 
genomic comparisons and identification of bacteria (mostly BLAST (41)); the prediction 
of secondary metabolite production from putative secondary metabolite gene clusters 
was implemented on antiSMASH (antibiotics and Secondary Metabolite Analysis SHell) 
software version 4.0.0 (42).  For phylogenetic analyses, Clustal Omega was employed 
(43). 
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Table 3-10 Most frequently used software for bioinformatics  
Software Hyperlink Reference 
antiSMASH http://antismash.secondarymetabolites.org/ (42) 
Clustal omega http://www.ebi.ac.uk/Tools/msa/clustalo/ (43) 
NCBI/BLAST https://blast.ncbi.nlm.nih.gov/Blast.cgi (41) 
PRINSEQ 
http://edwards.sdsu.edu/cgi-
bin/prinseq/prinseq.cgi?home=1 
(44) 
 
3.2. Microbiology methods  
3.2.1. Isolation of bacteria from environmental samples 
Environmental samples, i.e. sea sediment, algae, and marine mussels are put to dry for 
24 hours. Once humidity decreases, small portions of them are placed on WCX-ASW 
agar plates on top of E.coli suspension spots. The Petri plates are then incubated and 
bacterial growth is monitored daily. Bacteria displaying one or all of the following traits: 
gliding motility, pigment production, lysis of E. coli spots, are transferred to VY/4 – ASW 
and VY/2 agar plates. Bacteria able to grow in both media are considered halotolerant; 
bacteria able to grow only on VY/4 – ASW (marine medium) are considered halophilic; 
bacteria able to grow only on VY/2 medium are considered terrestrial.    
3.2.2. Gram staining modified from (45) 
The Gram staining was performed using a modified and thereby simplified version of the 
standard procedure. First, a smear of bacteria was produced on a glass slide and heat-
fixed using a Bunsen burner. 5 drops of crystal violet solution (2 g of crystal violet, 
dissolved in 10 ml ethanol, mixed with 50 ml water) were added and allowed to stand for 
1 minute.  
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The stain was then gently rinsed off with water. Next, 5 drops of a 0.05 M iodine solution 
were added. After 30 seconds, the iodine solution was washed off with water. 
Decolorising solution (equal volumes of 95 % ethanol and acetone) was added until the 
decoloriser running down the slide was colorless. The remaining solution was then 
washed off with water. As a counterstain, 5 drops of a 0.2 % safranin solution were 
added. The safranin solution was washed off after 20 seconds and after the slide had 
dried, it was analysed under a light microscope using 1,000-fold magnification. 
3.2.3. Preserving stock cultures  
Bacteria isolated from environmental samples and certified bacterial strains purchased 
were grown according to standard protocols for five days in broth and stored in cryovials 
with 1% casitone broth 1:1 (v/v) at - 80°C (long-term storage). Bacteria described in 
chapter 3 were stored with glycerol instead of casitone broth 1%. 
3.2.4. Cultivation of Labrenzia alba  
Strains of L. alba CECT were reactivated from freeze-dried cultures according to 
provider’s instructions and cultivated on marine agar plates; subsequently grown in 
marine broth in different scales, either for large-scale cultivation or small cultures for 
cryopreservation and storage purposes.  
3.2.5. Cultivation of bacteria isolated in our group 
Bacteria from chapter 2 and 3 were isolated accordingly as shown in section 3.2.1 and 
stored as described in section 3.2.3.  
3.2.6. Bacterial pre-cultures in marine broth 
Cryo cultures of the organism were thawed and placed in Petri dishes containing marine 
agar. The plates were incubated for three days. Thereafter, agar blocks of 1 cm were 
placed in 100 mL of marine broth previously adjusted to pH=7.6 with NaOH and 
incubated with shaking (120 rpm) at 30°C. These cultures were inoculated in 
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3.2.7. Large scale cultivation in marine broth 
3.2.8. Sterilization  
Every process intended to sterilize heat-resistant dissolutions, culture media, 
suspensions, and solid or liquid waste were carried out in steam sterilizers at 120°C for 
20 min. 
3.2.9. Disc diffusion test 
This is a qualitative assay to determine the antimicrobial capacity of extracts and pure 
substances isolated from our bacteria. It was conducted according to Schulz (46). The 
following Bacteria and fungi were used as test organisms: Bacteria: Escherichia coli DSM 
498, Bacillus megaterium DSM 32, Pseudoroseovarius crassostreae DSM 16950; fungi: 
Eurotium rubrum DSM 62631, Mycotypha microspora (this study), Microbotrium 
violaceum (this study)  
50 g of extract or pure compounds evaluated were taken from a solution of 1 mg/mL of 
extract or pure compound and applied on sterile paper discs on agar plates of the 
corresponding medium for each test organism. Thereafter, suspensions of the organisms 
were sprayed on the agar and incubated. Miconazole (50 g), streptomycin (50 g) and 
ampicillin (50 g) were used as positive controls. Inhibition zones were measured from 
the edge of the disc to the end of the area free of growth. Only total inhibition (>1mm) 
was considered as a positive result.    
3.2.10. Cytotoxicity test 
Dr. Nicole Merten kindly conducted cell viability assays in the group of Prof. Dr. Evi 
Kostenis. Cell viability was assessed using a fluorimetric detection of resorufin (CellTiter-
Blue Cell Viability Assay, Promega). HEK293 cells were seeded at a density of 27,000 
cells per well into black 96-well poly-D-lysine–coated plates with clear bottom. Three 
hours after seeding cells were treated with 0.3% DMSO or compound dissolved in 
medium for 24 h. To detect cell viability, CellTiter-Blue reagent was added and cells were 
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incubated for 1 h at 37°C according to the manufacturer’s instructions. Fluorescence 
(excitation 560 nm, emission 590 nm) was measured using a FlexStation 3 Benchtop 
Multimode Plate Reader and data were expressed as percentage of cell viability relative 
to DMSO control. (The cytotoxic anticancer drug etoposide was used as a positive 
control). 
3.3. Physical – chemical methods 
3.3.1. Liquid-liquid extraction 
This protocol is employed to separate substances between two immiscible solvents 
(aqueous-organic). Substances of interest were found in the organic phase of the 
system. This process was rutinarily done in glass-made separation funnels of different 
capacities.  
3.3.2.  Standard method for recovery of secondary metabolites  
Culture media with the organism of interest were added with 20 g of sepabeads 207 
(brominated styrene-divinylbenzene adsorbent media, Supelco, USA) per liter of culture 
after corresponding cultivation time for each microorganism and left in contact for 24 
hours in shaking condition at cultivation temperature (30°C). The resin was recovered 
and transferred into a suction strainer and washed with distilled water to remove adhered 
cells and hydrophilic compounds, e.g. sugars. Afterwards, the resin beads were 
exhaustively extracted with acetone to recover adsorbed substances (secondary 
metabolites mixed with unwanted compounds such as fat and similar). The acetone 
fraction containing the solids was evaporated yielding a crude extract, which was re-
dissolved in 60 mL DCM. This Solution was extracted three times with 50 mL aqueous 
methanol (60:40) according to section 3.3.1. The Organic phase was evaporated and 
the residue analysed with various instrumental techniques.  
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3.3.3. Vacuum liquid chromatography  
Normally, silica gel was used as stationary phase in the glass column capable to couple 
with vacuum pumps. The crude extracts were places atop the surface of the silica gel in 
the column and eluted with a gradient of increasing polarity, starting with petroluem ether 
as fist solvent, ethyl acetate as second solvent, acetone as third solvent, and methanol 
as fourth solvent. Amounts of solvents were used according to the needs of each 
experiment. The fractions collected were evaporated under vacuum and used for 
different biological testing. 
3.4. Molecular biology methods  
3.4.1. Genomic DNA isolation  
Axenic cultures of bacteria were retrieved from 100 mL of corresponding broth for each 
bacterium after 5 days of growth with constant shaking at 30°C. The bacterial genome 
was extracted for gene isolation and amplification purposes. The extraction protocol was 
conducted using the Wizard Genomic DNA Purification Kit (Promega, Mannheim, 
Germany).  
3.4.2. Polymerase Chain Reaction (PCR) 
PCR is an in vitro technique used for the amplification of genes of interest. Specific 
primers (pA/pH) complementary to the regions flanking the 16S rDNA gene were 
employed for identification of bacterial isolates. Standard conditions of PCR protocol are 
described in the following tables: 
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Table 3-11 Description of the amounts of each reagent necessary to carry out the PCR 
protocol for amplification of genomic sequences of interest. 
Reaction system 
Substance Volume 
5X Taq-buffer (green) 10.0 L 
DMSO 2.5 L 
dNTP mix (10mM) 1.0 L 
Forward primer (100 pmol) 1.0 L 
MgCl2 2.5 L 
Reverse primer (100 pmol) 1.0 L 
Taq DNA Polymerase (5 units/μl) 0.5 mL 
Template 2.0 L 
Water 29.5 L 
 
Table 3-12 Standard settings of the PCR thermal cycler devices.  
Step Temperature Time  
Initial denaturation  94°C 2 min  
Denaturation 94°C 45 sec 
30 cycles Annealing 55°C 1 min 
Elongation 72°C 1 min 
Final elongation 72°C 4 min  
 
3.4.3. Agarose gel electrophoresis  
Agarose gel electrophoresis is a common method used to separate DNA based on its 
molecular weight. Standard gels containing 1% electrophoresis grade agarose was used 
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to separate the DNA fragments. The electrophoresis was carried out with the running 
buffer (1X TBE) covering the gel. A volume range from 5-10 μl of 10 Kb DNA ladder was 
used as a standard size indicator. Electrophoresis was done in Horizon-58 and Horizon-
11.14 gel chamber (Life Technologies, Karlsruhe, Germany) at a voltage of 100V during 
40 min running time. To visualize the DNA, the gel was stained with ethidium bromide 
solution (10μg/ml) for 2 minutes. Subsequently, non-intercalated ethidium bromide was 
washed out for 2 minutes in demineralized water. DNA bands were visible under UV 
(254nm) and documented using intasiX imager (Intas Science Imaging Instruments 
GmbH, Göttingen, Germany). 
3.4.4.  DNA extraction from agarose gels 
DNA fragments separated in the agarose gel were extracted and purified using Wizard 
SV Gel and PCR Clean-Up system (Promega, Mannheim, Germany) as per the 
manufacturer’s instructions. The purified DNA was eluted with 30-50 μl water and stored 
at -20°C. 
3.4.5. Ligation of PCR- amplified fragments 
The PCR products were ligated into the plasmid using T4 DNA ligase. The reaction was 
performed in accordance to manufacturer’s protocol using the pGEM-T and pGEM-T 
Easy Vector Systems (Promega, Mannheim, Germany). The product was used for 
transformation of E. coli XL1 blue competent cells. 
3.4.6. Transformation of E. coli XL1 blue competent cells 
In order to maximize the amplification of the PCR products, the pGEMT easy vector and 
the inserts were cloned in competent cells available in the S1 laboratory of the Institute 
for Pharmaceutical Biology of the University of Bonn. In order to achieve this goal, the 
frozen competent cells were thawed on ice for 5 min. 5μl of the plasmid DNA were added 
to the bacterial suspension and incubated on ice for 30 min. Then the cells were heat- 
shocked at 42°C for 50 sec. The cells were then incubated again on ice for 2 min. To the 
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cold shocked cells 900μl of LB medium was added and incubated at 37°C with shaking 
at 160 rpm for 1 hr. The cells were then centrifuged at 13,000 rpm for 5 min. The cell 
pellet was then resuspended in 300 μl of fresh LB medium. 100 μl of the cell suspension 
was then plated on LB agar plate containing ampicillin (100 μg/ml) as the selection 
marker. The plate was then incubated overnight at 37°C. The first-appearing colonies 
were selected and incubated overnight in 2 mL Eppendorf vials containing 1 mL LB-
Ampicillin medium. Aliquots from each vial were then treated with the PureYield Plasmid 
Miniprep System in order to recover the plasmid. The final products were analysed by 
gel electrophoresis (section 3.4.3). The positive transformants were identified according 
to the expected size of the pGEM-T easy vector + PCR product (vector: 3 Kb + insert: 
0.8 Kb ≈ 4 Kb). The vials containing the matching-size recombinant plasmids were sent 
for sequencing.   
3.5. GPCR84 testing 
The tests involved in this section were kindly conducted in the group of Prof. Dr. Christa 
Müller. 
3.5.1. Biological assays 
The recombinant CHO cell line expressing the human GPR84 (CHO-hGPR84 cells) with 
a β-galactosidase fragment and arrestin containing the complementary fragment of the 
enzyme for performing β-arrestin recruitment assays based on enzyme complementation 
technology with a luminiscent readout (Pathhunter®) was purchased from DiscoverX 
(Fremont, CA). This cell line was used for the β-arrestin recruitment assays as well as 
for cAMP accumulation and radioligand binding assays. The CHO-hGPR84 cells were 
cultured in F12 medium supplemented with 10% FCS, 100 units/mL penicillin G, 100 
μg/mL streptomycin, 800 μg/mL G 418, 300 μg/mL hygromycin B, and 1% ultraglutamin 
(Invitrogen, Carlsbad, CA or Sigma-Aldrich, St. Louis, MO). Stock solutions of 
compounds including forskolin were prepared in DMSO (final DMSO concentration: 1 
%). Data were analysed using Graph Pad Prism version 6.0 (San Diego, CA, USA). 
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Concentration-response data were fitted by nonlinear regression to estimate EC50 
values. For the calculation of Ki values, the Cheng-Prusoff equation and a KD value of 
20.1 nM was used. 
3.5.2. Radioligand binding assays  
Radioligand binding assays were performed in 96-well plates as previously described 
(A). In brief, CHO cell membranes expressing GPR84 receptors (10 µg protein per vial) 
were incubated for 150 min at 25°C in 0.4 mL of a 50 mM Tris-HCl buffer (pH 7.4) 
containing 10 mM MgCl2, 0.05 % fatty acid free bovine serum albumin (BSA), 2 nM 
[³H]PSB-1584 (60 Ci/mmol) and increasing concentrations of test compound. 
Nonspecific binding was determined in the presence of 10 μM of unlabeled PSB-17365. 
Membrane-bound and free radioligand were separated by rapid filtration (GF/B-glass 
fiber filter) using a Brandel 96-channel cell harvester (Brandel, Gaithersburg, MD, USA) 
through Packard 96-well GF/B glass fiber filter plates. Filters were rinsed three times, 2 
ml each, with ice-cold 50 mM Tris-HCl buffer, pH 7.4. Radioactivity of the wet 96-well 
filter plates was counted after 6 h of preincubation with 50 µL of Microscint-20 scintillation 
cocktail (Perkin Elmer, Rodgau, Germany). Three independent experiments, each in 
duplicates were performed. 
3.5.3. cAMP accumulation assays  
cAMP assays were performed as previously described [B, C]. In short, CHO cells 
overexpressing the human GPR84 were stimulated by addition of forskolin (10 µM) in 
the absence (control) or presence of test compound for 15 min. The reaction was 
stopped by the addition of hot (90°C) lysis solution containing 4 mM EDTA and 0.01 % 
Triton X-100 in water. cAMP levels were quantified by a radioactive assay using 
[³H]cAMP (Perkin-Elmer, Rodgau, Germany) and a cAMP binding protein prepared from 
bovine adrenal medulla. The forskolin-induced increase in cAMP concentration in the 
presence of test compound was expressed as percentage of the response to forskolin in 
Materials and methods  
30 
 
the absence of agonist (% of control). Three independent experiments, each in 
duplicates were performed. 
3.5.4. β-Arrestin recruitment assays  
β-Arrestin assays were performed as previously described [B, C]. Briefly, CHO cells 
expressing the human GPR84 with a β-galactosidase fragment and β -arrestin containing 
the complementary fragment of the enzyme (20,000 per well) were incubated with 
compound dilutions (in DMSO, final concentration: 1 %) for 90 min before adding the 
detection reagent (DiscoverX®). After 60 min of incubation at rt, the luminescence was 
measured using an NXT plate reader (Perkin-Elmer, Rodgau, Germany). Three to five 
independent experiments were performed, each in duplicates. 
3.6. Instrumental analyses 
3.6.1. Flash chromatography  
For the first fractionation step of the crude extracts from the adsorption resin, a 
Reveleris® X2 chromatography system with evaporative light scattering detector 
(ELSD), UV detector, equipped with dry air supply was used. The column chosen was 
using a Reveleris silica column of 12 g (12 mg – 2.4 g sample load capacity, 12 m). The 
mobile phase consisted of gradients of PE/Acetone. Equilibration time was 7.1 min. UV 
and ELSD detection thresholds were 0.05 AU and 20 mV, respectively. High ELSD 
sensitivity was chosen, slope detection high and dry flash mode. The flow rate typically 
used was 30 mL/min.   
3.6.2. High Performance Liquid Chromatography 
High performance liquid chromatography was executed on a Merck-Hitachi L-6200A 
Intelligent Pump device coupled to a diode array detector L-4500A. Mobile phases 
consisted of Water/MeOH and Water/ACN, each component added with H3PO4 at a 
concentration of 0.1 M). The column YMC-triart C18 / S-5m /12 nm (250 x 4.6 mm I.D) 
was employed for this purpose. The typical flow rate was 1 mL/min.  
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3.6.3. Mass Spectrometry  
Mass spectra were recorded on a micrOTOF-Q mass spectrometer (Bruker) with ESI-
source coupled with an HPLC Dionex Ultimate 3000 (Thermo Scientific) using an Agilent 
Zorbax Eclipse Plus C18 column (2.1 x 50 mm, 1.8 m). The column temperature was 
45 degree Celsius. HPLC begins with 90% H2O containing 0.1% acetic acid. The 
gradient starts after 1 min to 95% Acetonitrile (0.1% acetic acid) in 4 min. 2 L of a 
1mg/mL sample solution was injected to a flow rate of 0.8 mL/min.   
3.6.4. Nuclear Magnetic Resonance Spectroscopy 
All NMR spectra were recorded on a Bruker UltraShield operating at 300 MHz (1H) and 
75 MHz (13C) with CDCl3 as the solvent. Spectra were referenced to residual solvent 
signals with resonances at H/C-7.26/77.16 for CDCl3. The multiplicity of the carbons 
was deduced by DEPT135 experiments. Structural assignmnts were based on spectra 
resulting from the following NMR experiments: 1H, 13C, DEPT135, 1H-homonucelar 
decoupling, 1H-1H-COSY, 1H-13C-HSQC (direct correlation), 1H-13C- HMBC (long-
range correlation), 1H-1H- NOESY.   
3.6.5. UV-Visible spectrometry  
UV spectra were recorded on a Perkin-Elmer Lambda 40 with UV WinLab Version 
2.80.03 software. Quartz cells of 1 cm length were selected.  
3.6.6. Polarimetry  
Optical activity measurements were carried out on a Jasco J-810 spectropolarimeter with 
sodium lamp.
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 CHAPTER 1: Genome mining of myxobacteria grouped in the   
suborder Nannocystineae 
 
4.1. Prefatory matters 
Myxobacteria are famous for their ability to produce most intriguing secondary 
metabolites. Till recently, only terrestrial myxobacteria were in the focus of research. In 
this chapter, however, we discuss marine-derived myxobacteria, which are particularly 
interesting due to their relatively recent discovery and due to the fact that their very 
existence was called into question. The to-date-explored members of these halophilic or 
halotolerant myxobacteria are all grouped into the suborder Nannocystineae. Few of 
them were chemically investigated revealing around 11 structural types belonging to the 
polyketide, non-ribosomal peptide, hybrids thereof or terpenoid class of secondary 
metabolites. A most unusual structural type is represented by salimabromide from 
Enhygromyxa salina. In silico analyses were carried out on the available genome 
sequences of four bacterial members of the Nannocystineae, revealing the biosynthetic 
potential of these bacteria. 
4.2. Taxonomy and ecology of myxobacteria 
Bacteria from the order Myxococcales, commonly known as myxobacteria, are Gram-
negative, rod-shaped -proteobacteria, comprising compared to many other bacteria 
large genomes. The 14,782,125 bp large genome of Sorangium cellulosum So0157-2 is 
the largest bacterial genome reported to date (47). Myxobacteria are able to glide over 
surfaces in swarms in order to facilitate heterotrophic nutrition on macromolecules as 
well as on whole microorganisms, a distinctive trait of these bacteria (48). Additionally, 
under adverse environmental conditions, e.g. nutrient shortages, high temperature and 
dryness, individuals cooperate to create intercommunicated multicellular myxospore-
containing fruiting bodies in order to ensure the distribution of nutrients they can still 
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harness, allowing germination as soon as conditions are favorable for the vegetative 
phase again (49). Based on our experience in the laboratory, fruiting bodies can occur 
on solid surfaces like agar plates, as well as in liquid cultures. These adaptive strategies 
play a fundamental role on how these organisms are able to endure under unfavorable 
conditions (50, 48). In terms of oxygen demand for growth, myxobacteria were thought 
to be strictly aerobic until the only anaerobic genus known to date, Anaeromyxobacter, 
was reported in 2001 (51). Also, for many years myxobacteria were considered to 
typically occur only in terrestrial habitats and much has been published in terms of their 
morphology, physiology and ecology (50, 48, 52, 53). 
Recently, ever more myxobacteria from intertidal and marine environments were 
reported. According to salt requirements for growth, a straightforward classification of 
these bacteria has been provided (2): (I) halotolerant strains are capable to grow with or 
without NaCl; and (II) halophilic bacteria are unable to grow without sea salt. Bacteria of 
group (I) may be derived from terrestrial organisms, which have adapted to saline 
conditions, whereas those of group (II) may be of truly marine origin. 
A typical halotolerant myxobacterium, originally obtained from coastal samples, is the 
Myxococcus fulvus strain HW-1 (suborder Cystobacterineae). In this case, it was 
demonstrated that salt concentration not only affects growth, but also myxobacterial 
motility systems as well as fruiting body formation (54). In the absence of salt, both 
capabilities were diminished. Mutational studies imply that the single, probably 
horizontally transferred gene hdsp, which was found in five halotolerant Myxococcus 
strains, but not in soil-derived Myxococcus strains, leads among other changes to sea 
water tolerance (55).  
Only few myxobacteria dwelling in sea habitats are considered as halophilic, that is, of 
true marine origin. Indeed, early isolates from marine environments were thought to be 
halotolerant terrestrial myxobacteria whose myxospores had been washed into the 
ocean (56).  
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This opinion prevailed until Fudou and Iizuka (57–60) discovered the first strictly 
halophilic myxobacteria within the suborder Nannocystineae, namely Enhygromyxa, 
Haliangium, and Plesiocystis, which strictly require sea-like salinity conditions in order to 
grow. Whether the adaptation to the marine environment was acquired independently 
several times, or if these entire marine clades share one common ancestor, is not 
clarified yet due to the relatively low number of species known to date. 
Regarding the strategies employed by these bacteria to cope with salt and desiccation 
stress, the accumulation of organic osmolytes instead of the salt-in strategy can be 
expected. This hypothesis is supported by the fact that all strains investigated so far can 
grow within a relatively wide range of salinity. Also, the terrestrial strain M. xanthus, which 
is slightly halotolerant, uses organic osmolytes, i.e. glycine betaine to combat osmotic 
stress (61). Analyses on the osmoprotective strategies of Enhygromyxa salina SWB007 
and Plesiocystis pacifica SIR-1 revealed that both closely related strains rely on organic 
osmolytes. For instance, E. salina SWB007 biosynthesizes the osmolytes betaine, 
ectoine, and especially hydroxyectoine under high salt concentrations. In contrast, P. 
pacifica SIR-1 does not synthesize specialized compatible solutes; this strain rather 
accumulates amino acids as osmoprotective agents (62). Of course, further mechanisms 
may be involved for osmoregulation, but are unknown to date for myxobacteria. A list of 
general bacterial osmoregulation processes is given elsewhere (63). 
4.2.1. Secondary metabolites from myxobacteria 
Members of the order Myxococcales are famous for their ability to produce secondary 
metabolites of diverse chemical nature with the capability to exert different biological 
effects (64, 65). Detailed descriptions of myxobacteria-derived metabolites can be found 
in various detailed reports (65, 64, 66–68). The majority of these metabolites are either 
non-ribosomal peptides, e.g. cystobactamids 1-3 (69), polyketides, e.g. aurafuron A 4 
(70), or hybrids thereof, e.g. corallopyronin A 5 (71). 
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Figure 4-1 Structures of cystobactamids 507, 919-1 and 919-2. 
Cystobactamid 507      1 
Cystobactamid 919-2      3 
Cystobactamid 919-1      2 
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Figure 4-2 Structures of aurafuron A and corallopyronin      
                        
Interestingly, an ample amount of them was shown to work as antimicrobial agents, 
above all corallopyronin A. This is probably a reflection of their predatory habits (72, 73). 
A comprehensive description of antibiotics obtained from myxobacteria can be found in 
a previous review (66). One outstanding example of a biologically active PKS/NRPS-
derived compound, produced by the terrestrial S. cellulosum is the microtubule stabilizer 
epothilone B. Its lactam analog, ixabepilone 6 is currently used together with 
capecitabine 7 in cancer therapy to improve the effectiveness of taxane-resistant 
metastatic breast cancer treatment, demonstrating the therapeutic potential of 
myxobacterial secondary metabolites (74–76). This drug has also been assessed as 
chemotherapeutic agent in pancreatic lymphoma showing promising results and 
tolerable toxicity (77).  
Aurafuron A 4 
Corallopyronin A 5 
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Figure 4-3 Structures of ixabepilone and capecitabine. 
 
Over time, different strategies have been designed to tackle the sometimes-cumbersome 
task of finding bioactive secondary metabolites of bacterial origin, i.e. mainly bioactivity- 
or chemistry-guided methods. An additional approach, complementary to the latter, 
arose in the late 1990s, when the first microbial genomes were sequenced, allowing 
genome mining. Thus, knowledge derived from bioinformatic analysis of microbial 
genomes paved the way to gain detailed insights into bacterial secondary metabolism. 
Since then, in silico methods for genome mining have enormously advanced, and 
effective experimental approaches for connecting genomic and metabolic information 
have been developed (78–80).  
The terrestrial Myxococcus xanthus strain DK1622 was the first myxobacterium to have 
its 9.14 Mb genome sequenced, with the initial aim to study its swarming motility and 
fruiting body formation (81). At the same time, this work reinforced the notion that large 
genomes often correlate with the potential for prolific secondary metabolite production 
by revealing almost 8.6% of the genome to be possibly involved in the biosynthesis of 
secondary metabolites (81). Mining this genome for the presence of PKS and NRPS 
genes exposed 18 biosynthetic clusters, with a predominance of hybrid PKS-NRPS 
Ixabepilone 6 (Derived from the 
myxobacterial epothilone B (Hunt 2009) 
Capecitabine 7 
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systems (82). M. xanthus strain DK1622 is responsible for the synthesis of metabolites 
like DKxanthene-534 8, a pigment required for fruiting body formation and sporulation 
processes (82) and the siderophore myxochelin A 9, which belongs to a class of 
compounds that have recently been shown to have antiproliferative effects on leukemic 
K-562 cells (72). 
 
 
 
 
Figure 4-4 Structures of DKxanthene-534 and myxochelin A. 
. 
Halotolerant and halophilic marine myxobacteria are poorly investigated regarding 
secondary metabolite production. Therefore, the pool of secondary metabolites isolated 
from organisms of this kind is very low to date, when compared to that of their terrestrial 
counterparts. This is mainly due to the difficulties that are encountered during isolation 
and cultivation processes of marine myxobacteria. However, herein we intend to show 
DKxanthene-534 8 
Myxochelin A 9 
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that these organisms are a great research niche, which offers the opportunity to find 
novel bioactive compounds with the potential to become drug leads.  
Regarding halotolerant myxobacteria, the 9 Mb genome of the Myxococcus fulvus strain 
HW-1 (ATCC BAA-855, suborder Cystobacterineae) was the first-of-its-kind to be 
sequenced (83). Genome mining performed in our group revealed that this organism 
displays, analogous to the previously discussed example M. xanthus strain DK1622, a 
plethora of cryptic gene clusters, e.g. five NRPS, four hybrid PKS-NRPS, one PKS-
NRPS-lantipeptide, three lantipeptide and numerous bacteriocin- and terpene-encoding 
gene loci. A more detailed comparison revealed that both strains share the majority of 
their gene clusters, among them the aforementioned DKxanthene, the myxochromide 
(65) and myxoprincomide (84) pathways, besides other, yet uncharacterized loci. It is 
worth mentioning that no gene clusters involved in synthesis of osmolytes like betaine 
and ectoine were detected in the halotolerant bacterium. 
4.3. Taxonomy, cultivation and secondary metabolite chemistry of marine-
derived myxobacteria (Nannocystineae) 
The following sections summarize features of three halotolerant and four marine-derived 
bacterial taxa clustered in the suborder Nannocystineae: Nannocystis, Haliangium, 
Enhygromyxa, Plesiocystis, Myxobacterium SMH-27-4 (i.e. Paraliomyxa) and 
Pseudenhygromyxa (see Figure 4-5). 
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Figure 4-5 Phylogenetic tree of halotolerant and halophilic myxobacteria. The neighbor-
joining tree is based on a multiple sequence alignment (MSA) of the 16S rDNA 
sequences. The terrestrial myxobacteria Myxococcus xanthus DK1622, Sorangium 
cellulosum Soce56as and Escherichia albertii DM104 are included for comparison. MSA 
was computed using MAFFT (Multiple Alignment using Fast Fourier Transform).  
 
Information on strain isolation, culture conditions, phylogeny, genetics and hitherto 
isolated molecules will be provided, with an emphasis on structural details and biological 
activity of the metabolites. Additionally, putative gene clusters for secondary metabolite 
biosynthesis are included in this work. For this reason we were mining the four available 
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genomes from bacteria of the Nannocystineae using the antiSMASH (42)(see Table 4-
1). The genome mining results are generated by feeding the software with the accession 
number (AN) of the annotated sequences. The databases are continuously updated, 
thus, results presented in this part of the work may vary in ulterior analyses. Our data, 
however, present a useful guide for future projects. For detailed information on terrestrial 
myxobacteria and other predatory bacteria, readers are referred to the review article from 
Korp (85). 
 
Table 4-1 Summary of antiSMASH analysis (version 4.0.0) of the four available genomes 
of myxobacteria of the suborder Nannocystineae 
 
Halophilic/Halotolerant Terrestrial 
Enhygromyxa 
salina            
DSM 15201 
Plesiocystis 
pacifica SIR 1 
Haliangium 
ochraceum 
DSM 14365 
Nannocystis 
exedens 
ATCC 25963 
Genome size (Mb) 10.44 10.59 9.45 11.61 
GC% 67.4 70.7 69.5 72.2 
Number of contigs 330 237 1 174 
% of genome involved in 
secondary metabolism1 
9.2 6.4 10.1 8.2 
Total number of clusters 38 28 25 31 
NRPS 2 1 3 1 
PKS (including PKS 
hybrids) 
13 11 2 2 
NRPS/PKS hybrids 2 0 3 6 
Terpene 7 6 3 10 
Bacteriocin 6 6 5 3 
Ribosomal peptides 0 0 4 1 
Marine-derived myxobacteria of the suborder Nannocystineae 
42 
 
Siderophore 2 1 0 2 
Indole 1 0 0 0 
Arylpolyene 2 1 0 2 
Phenazine 0 0 0 2 
Ectoine 0 0 1 0 
Other 3 2 4 2 
1Total bases of all detected antiSMASH secondary metabolite gene clusters divided by number 
of bases in the genome. 
 
4.4. The genus Nannocystis 
Bacteria of the genus Nannocystis are merely halotolerant and frequently isolated from 
terrestrial or intertidal regions. Back in the 1970s, the Reichenbach group informed on 
the isolation of a widely distributed soil-dwelling myxobacterium similar to members of 
the genus Sorangium in terms of cytology and growth pattern (86). After taxonomic 
studies, they proposed a new genus and species, i.e. Nannocystis exedens. Only 
recently, it has been recognized that members of this genus have a great potential as 
producers of metabolites with relevant biological activities. One striking example is the 
2015 described nannocystin A 10, a macrocyclic compound of NRPS-PKS origin with 
strong antiproliferative properties isolated from the terrestrial Nannocystis sp. ST201196 
(DSM 18870) (87). 
Marine-derived myxobacteria of the suborder Nannocystineae 
43 
 
 
 
Figure 4-6 Structure of nannocystin A. 
It was subsequently shown that nannocystin A targets the eukaryotic translation 
elongation factor 1, a promising novel target for cancer therapy (87). Regarding 
metabolites from halotolerant Nannocystis strains, the most outstanding examples are 
the phenylnannolones A-C 11-13, molecules of polyketide nature with a phenylalanine-
derived starter unit (88). 
 
 
 
 
 
 
Nannocystin A 10 
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Figure 4-7 Structure of phenylnannolones A-C. 
These compounds are synthesized by N. exedens strain 150, later reassigned to N. 
pusilla, isolated from the intertidal region of a beach in Crete (88). Cultivation of the 
regarding organism was carried out in liquid medium with the addition of adsorber resin. 
The adsorbed metabolites were then extracted and isolated via different 
chromatographic techniques. Phenylnannolone A 11 was found to be the main 
metabolite, which is accompanied by only minute amounts of the other derivatives 12 
and 13. Phenylnannolone A was proven to restore daunorubicin sensitivity in cancer cells 
by inhibiting P-glycoprotein (P-gp), an ATP-binding cassette transporter (ABC 
transporter). In tumor cells, P-gp serves as an efflux transporter of drugs, ultimately 
leading to treatment failure (89). 
Apart from these polyketides, an array of nitrogen-containing metabolites was published 
recently by Jansen (90). They investigated three strains of N. pusilla isolated from coastal 
sediment samples - deemed halotolerant for this reason - for their secondary metabolite 
production. Two strains, Ari7 and Na a174 yielded a new class of halogenated pyrrole-
oxazole compounds 14-18. Pyrronazols A 14, A2 15 and B 16, synthesized by Ari7, 
additionally include an -pyrone-moiety (91).  
R1 = CH3, R2 = H Phenylnannolone A 11 
R1 = H, R2 = H Phenylnannolone B 12 
R1 = CH3, R2 = OH Phenylnannolone C 13 
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This is worth noting, since the non-cyclic alkyl moiety in the pyrronazols C1 17 and C2 
18, found in strain Na a174, is supposed to be a result of degradation processes due to 
long-time cultivation. Additionally, the known compound 1, 6-dihydroxyphenazin 19 and 
its arabinofuranoside 20 were obtained.  
To date, 14 has shown marginal antifungal activity towards Mucor hiemalis (DSM 2656) 
(MIC: 33.3 g/mL) and 19 proved to have cytotoxic effects in the lower micromolar range 
against different cancer cell lines (90).  
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Figure 4-8 Structures of the pyrronazols, Dihydroxyphenazin and 1-hydroxyphenazin-6-
yl-α-D-arabino-furanoside.  
Pyrronazol A 14 
Pyrronazol A2 15 
Pyrronazol B 16 Pyrronazol C1 17 
Pyrronazol C2 18 1,6-Dihydroxyphenazin 19 
1-Hydroxyphenazin-6-yl--D-arabinofuranoside 20 
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Nannozinones A 21 and B 22 are produced by N. pusilla strain MNa10913, isolated from 
a soil sample, collected in Mallorca, Spain (92). They represent novel pyrazinone type 
molecules. Additionally, the siderophore nannochelin A 23 also from other myxobacteria 
was isolated (93). 
 
 
 
Figure 4-9 Structures of nannozinones A + B and nannochelin A from N. pusilla strain 
MNa10913. 
 
All three compounds were tested against a broad range of microorganisms and 
mammalian cell lines. The most relevant antimicrobial activity was shown by 21 towards 
Mycobacterium diernhoferi (DSM 43542), Candida albicans (DSM 1665) and Mucor 
hiemalis (DSM 2656) (33.3 g mL-1 in each case).  Significant cytotoxic activity was 
revealed for 22 towards SKOV-3 (IC50 = 2.4 M), KB3-1 (IC50 = 5.3 M), as well as A431 
(IC50 = 8.45 M), while 23 showed remarkable cytotoxicity against cell lines HUVEC and 
KB3-1(IC50 = 50 nM).  
Nannozinone A 21 Nannozinone B 22 
Nannochelin A 23 
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So far, no genome sequence is publicly available for halotolerant strains of this genus. 
The only sequence found in the databases belongs to the terrestrial N. exedens ATCC 
25963 (see Tabe 4-1). Remarkably, this genome encodes, among a considerable 
number of NRPS/PKS hybrids, 10 different terpene biosynthesis gene clusters. 
4.5. The genus Haliangium 
Haliangium ochraceum sp. nov. (Initially termed H. luteum, DSM 14365T) and H. tepidum 
sp. nov. (DSM 14436T) were isolated from seaweed and sea grass, respectively, with 
both samples being obtained from a sandy beach in Miura, Japan by Fudou in 2002 (57). 
The species were proposed to be of true marine origin according to their salt requirement 
for growth. Indeed, 2 to 3 % NaCl (w/v) and a pH of 7.5 are optimal for growth on yeast 
medium with artificial seawater solution. These conditions were established for routine 
isolation and cultivation. One particular feature worth mentioning is that the species have 
rather different optimal growth temperature intervals: 30-34 °C for H. ochraceum and 37-
40 °C for H. tepidum. According to the original report, both strains share 95.5% of 16S 
rDNA sequence identity and have the terrestrial Kofleria flava (DSM 14601) as their 
closest relative (16S rDNA sequence identity lower than 95%). The GC content of H. 
ochraceum and H. tepidum is 67 and 69 mol%, respectively. 
H. ochraceum was found by Fudou (94) to be a producer of secondary metabolites with 
antibacterial and antifungal activities. Further investigation led to the isolation and 
structure elucidation of the bioactive polyketide haliangicin 24, which was the first 
myxobacterial metabolite of true marine origin.  
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Haliangicin 24 
Figure 4-10 Structure of haliangicin from H. ochraceum. 
 
It was found that this molecule comprised a β-methoxyacrylate sub-unit including a 
conjugated tetraene moiety (95). The complete structure was elucidated via 2D-NMR-
techniques, while NOESY correlations were used to study the configuration of the double 
bonds. However, the configuration at the epoxide bearing carbon atoms could not be 
resolved at that time. In further work, Kundim (96) published three new haliangicin 
stereoisomers, which differed in the configuration of the three terminal double bonds in 
the tetraene moiety. Each of the isomers haliangicin, haliangicin B, haliangicin C and 
haliangicin D happened to be present with two different configurations around the epoxy 
group. The NOESY spectra showed correlations for the cis- and trans-configuration. 
However, the absolute configuration of the chiral centers could not be resolved yet. 
Moreover, the origin of the different isomers is not clear. Due to their alleged instability 
upon exposure to air and light, one could speculate that isomerization occurs during the 
purification process. Interestingly, the authors found a NaCl-dependent production of 
haliangicin (94). The optimal production range is at 2-3 % NaCl (w/v) in the medium, 
which is the same range as for optimal growth. Haliangicin showed activity against some 
fungal organisms, e.g. Aspergillus niger (AJ117374) (MIC: 12.5 g mL-1) and Fusarium 
sp. (AJ177167) (MIC: 6.3 g mL-1). These MIC values were in a similar range as those 
of known antifungal compounds such as amphotericin B or nystatin against the same 
fungi (MIC: 3.1 g mL-1for both compounds).  
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Recently, the 9.4 Mb genome of H. ochraceum (DSM 14365T) was completely 
sequenced and published (97). This was the first marine-derived myxobacterium to have 
its genome fully determined. We performed an antiSMASH analysis on the genome of 
H. ochraceum (DSM 14365T) (AN: CP001804.1). The results revealed the presence of 
25 secondary metabolite gene clusters, among them three NRPS, two PKS, three 
NRPS/PKS and four ribosomal peptides (see Tabe 4-1).  Apart from homologies to 
geosmin (100%), aurafuron (71%) and paneibactin (50%) biosynthetic genes, the gene 
clusters display a large degree of novelty. Recently, the biosynthetic gene cluster of 
haliangicin was heterologously expressed in Myxococcus xanthus, leading to tenfold 
higher haliangicin production than in the native producer. Insights into its biosynthesis 
were gained by feeding studies with labeled precursors and in vitro experiments. 
Additionally, unnatural haliangicin analogs that provided insights into the structure-
activity-relationship of haliangicin were generated in this study (98).The huge potential 
to synthesize novel metabolites in the genus Haliangium is further corroborated by a 
PCR screening-based study for PKS sequences in H. tepidum among other 
myxobacteria (99). The authors found H. tepidum to contain the highest amount of novel 
PKS sequences in this array. Additionally, the indications at the genetic level are 
reinforced by the very recent discovery of a new compound produced by H. ochraceum 
SMP-2, i.e. haliamide 25. The authors also describe the corresponding hybrid PKS-
NRPS machinery responsible for metabolite biosynthesis (33). The molecule was shown 
to have cytotoxic effects towards HeLa-S3 cells (IC50 = 12 M). 
 
Haliamide 25 
Figure 4-11 Structure of haliamide from H. ochraceum SMP-2. 
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4.6. The genus Enhygromyxa 
All Enhygromyxa species isolated to date are halophilic and considered as truly marine 
myxobacteria. The initial report on isolation, characterization and taxonomic 
classification of six strains of E. salina, SHK-1T, SMK-1-1, SMK-1-3, SMK-10, SKK-2, 
and SMP-6, was published in 2003 by Iizuka (59). These organisms were obtained 
respectively from mud, sand and algal samples collected in marine environments around 
Japan. Later, four additional strains of E. salina were isolated by the group of König from 
marine-intertidal sediment samples collected at the West Coast of the USA, at German 
coasts and the Netherlands (100, 101). Recently, existance of strain SNB-1 was reported 
(102). This organism was isolated from a marine mud sample collected in 1998 at a 
beach in Kashiwazaki, Niigata (102). 
As judged from these varied geographical occurrences a worldwide distribution of 
Enhygromyxa species is likely. 
The prior mentioned groups reported 1-2 % NaCl (w/v) and a pH interval of 7.0-8.5 for 
optimal growth on yeast medium. The optimal temperature for growth was determined 
as 28-30 °C. In terms of gliding motility, fruiting body, and myxospore formation, these 
bacteria show the typical features of terrestrial myxobacteria. A salt-dependency and 
high G+C content ranging from 65.6 to 67.4 mol% (59) and 63.0 to 67.3 mol% (101) were 
also observed in some organisms. Based on 16S rDNA sequence alignments, E. salina 
SHK-1T (NR_024807) from Iizuka (59) was found to be most closely related to the E. 
salina strains from the König group (101). The 16SrDNA sequences of these strains 
share between 98% (SWB004, AN: HM769727) and 99% (SWB005, AN: HM769728; 
SWB006, AN: HM769729; SWB007, AN: KC818422) identity. 
Some of the bacterial isolates were originally evaluated for their ability to produce PKS-
type metabolites and for the biosynthesis of antimicrobials (101). 
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 In these studies, PKS genes could be amplified, sequenced and compared with known 
sequences in the BLAST database. The potential of producing active molecules was 
established by using disc diffusion antibiotic activity testing of the bacterial extracts, 
whereby an inhibitory effect of the extracts of E. salina SWB005 on various test 
organisms, including the clinically relevant MRSA (methicillin resistant Staphylococcus 
aureus) strains LT1334, LT1338 and MRSE methicillin resistant Staphylococcus 
epidermidis strain LT1324 was observed (101).  
To date, five structures of putative polyketide, shikimate and terpenoid origin have been 
described and classified as salimabromide 26 (100), produced by E. salina SWB007, 
enhygrolides 27, 28 and salimyxins 31, 32 produced by E. salina SWB005 (103). 
Recently, three novel structures have been isolated from E. salina SNB-1, namely 
deoxyenhygrolides 29, 30 and enhygromic acid 33, compounds of PKS and terpenoid 
nature, respectively (102). These structures are illustrated in Figure 4-12. 
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Figure 4-12 Structures of salimabromide, enhygrolides A + B, deoxyenhygrolides A + B, 
salimyxins A + B and enhygromic acid. 
 
Salimabromide 26 Enhygrolide A 27 
Enhygrolide B 28 
Salimyxin A 31 Salimyxin B 32 
Z: deoxyenhygrolide A 29 
E: deoxyenhygrolide B 30 
Enhygromic acid 33 
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Salimabromide 26 is particularly interesting due to its unique halogenated tetracyclic core 
structure. Its biosynthesis is postulated to be carried out by a type III-PKS. Pure PKS-
derived compounds are rare in myxobacteria, which together with the new carbon 
skeleton and the high bromination level makes this structure even more fascinating. 
Structure elucidation was achieved via extensive NMR-measurements. The absolute 
configuration of the chiral centers could be resolved through comparison of the 
experimental CD-spectrum with calculated data. This metabolite showed inhibitory 
activity towards the bacterium Arthrobacter crystallopoietes with an MIC value of 16 g 
mL-1. Further bioactivity assays were impossible to carry out due to the minute amounts 
in which this metabolite is produced. Consequently, a synthetic approach has been 
utilized in order to overcome this problem, leading so far to the synthesis of the tricyclic 
core structure of the molecule. However, the complete natural product has not yet been 
synthesized (104).     
The enhygrolide group of compounds comprises enhygrolide A 27 and B 28. These 
molecules resemble cyanobacteria-derived metabolites, known as nostoclides and 
cyanobacterin, which also have a γ-lactone-moiety with a similar substitution pattern. In 
the myxobacterial metabolites an E-configuration was found at the benzylidene-unit, 
whereas the nostoclides and cyanobacterin have a Z-configuration. Only the anhydro 
form of cyanobacterin was found to isomerize from the Z- to the E-configured isomer in 
organic solvents upon light exposure (105). Deoxyenhygrolide A 29 and 
deoxyenhygrolide B 30 are analog structures to 27 and 28, the only difference is the lack 
of –OH group on the para position of the aryl moiety. To date, no activities have been 
assigned to these compounds.    
The salimyxins represent the third group of compounds, i.e. salimyxin A 31 and B 32. 
These belong to a subgroup of terpenoids named incisterols, which were first discovered 
from the sponge Dictyonella incisa (106).  
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Their biosynthesis presumably involves oxidative degradation of a sterol, leading to the 
tricyclic core structure. 
 Compounds 27 and 30 have shown inhibitory activity towards A. crystallopoietes (MIC 
value of 8 and 4 g mL-1, respectively).  
Compound 33 represents a novel structure displaying a tricyclic skeleton linked to a -
meta acrylate acid chain. Bioinformatic-oriented investigations suggest a terpenoid 
biosynthetic origin (102).  This research group conducted bioactivity tests whereby this 
compound exhibited cytotixic activity against B16 melanoma cells (IC50 = 46 M) and 
antimicrobial properties against the Gram-positive bacterium Bacillus subtillis (8 g/mL).   
Since salimabromide is a novel structure of putatively assigned PKS origin, our research 
group sequenced the genome of the producing strain SWB007. The results revealed a 
PKS III gene cluster adjacent to a halogenase sequence (unpublished data). Upon 
sequencing, primers for these genes were designed. Given the genetic proximity among 
the E. salina isolates, strains SWB004, SWB005 and SWB006 were screened with the 
PKS III and halogenase primers specific for the SWB007 sequence revealing the 
presence of close-to-identical sequences in their genomes (unpublished data), a clear 
suggestion that similar molecules may be also produced by the related strains. 
Bioinformatic analysis was performed by us on the available genome of E. salina (DSM 
15201) (AN: JMCC00000000.2) of which as to date, no reports on the isolation of 
compounds are available. However, the screening with antiSMASH revealed an ample 
amount of uncharacterized biosynthetic gene clusters, among them 17 gene clusters 
putatively responsible for the synthesis of NRPS, PKS and hybrid NRPS-PKS products 
(see Tabe 4-1). Apart from the geosmin biosynthesis genes, no gene cluster or fragment 
thereof shares an identity higher than 33% to any known gene cluster in the MiBIG 
database (107).  
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It should be noted that since this is a draft genome sequence, the actual amount of gene 
clusters might be slightly smaller since small contigs display only fragments of gene 
clusters.  
4.7. The genus Plesiocystis 
In 2003 Iizuka (60) proposed the genus and the species Plesiocystis pacifica for the 
myxobacterial strains SHI-1 (JCM 11592, DSM 14876) and SIR-1T (JCM 11591T, DSM 
14875T). SHI-1 was retrieved from a sand sample of a Japanese coastal area, whilst 
strain SIR-1T was isolated from a piece of dried marine grass (Zostera sp.). These strains 
require 2 - 3 % NaCl (w/v) and a pH of 7.4 for optimal growth on yeast medium with 
artificial seawater solution at 28 °C.  
According to Iizuka (60) the isolates are closely related, sharing 99.5% 16S rDNA 
sequence identity between them. Their closest relative was reported to be Nannocystis 
exedens DSM 71T, with 89.3% sequence identity to SIR-1T and 89.4% to SHI-1. 
Regarding GC content, SIR-1T and SHI-1 were reported to have 69.3 and 70.0 mol%, 
respectively. Such a high GC content is a distinctive trait of all myxobacteria. To date, no 
reports on biological testing of extracts or of any metabolites isolated from these 
organisms have been published. The antiSMASH analysis was performed on the 
available draft genome of P. pacifica strain SIR-1 (AN: ABCS00000000.1). The analysis 
revealed the presence of 12 NRPS, PKS and hybrid NRPS-PKS gene clusters amongst 
many others (see Table 4-1), which should encourage researchers to isolate some of 
the predicted metabolites. Here, no gene clusters sharing more than 28 % identity to 
pathways of characterized molecules were detected. Again, many of the PKS and NRPS 
gene cluster appear to be fragmented to smaller contigs.  
4.8. Myxobacterium SMH-27-4 (Paraliomyxa miuraensis) 
In 2006, as a result of the remarkable efforts of Iizuka (108) a novel myxobacterium was 
isolated from a soil sample of a seashore area in Miura, Japan.  
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After genetic analysis, the new isolate was classified as strain SMH-27-4, tentatively 
named Paraliomyxa miuraensis. This strain is considered slightly halophilic. Yeast 
medium with only a low sea salt concentration was selected for isolation, whereas 
cultivation in NaBr-containing medium was selected for antibiotic production. The 
diminished strength of salinity in the medium implies an optimal salt range concentration 
for growth of 0.5-1 % (w/v), at pH = 7.2 and a temperature of 27 °C.  Fermentation and 
the production of antibiotic compounds was performed at 27 °C at pH 7.3. 
Surprisingly, the authors do not report fruiting body formation during the cultivation of 
myxobacterium SMH-27-4, which usually is a hallmark feature of myxobacteria. 
Phylogenetic analyses carried out by Iizuka (108) revealed that this organism shares 
93.0% identity with Nannocystis exedens DSM 71T (AB084253), 93.2 to 93.3% with 
Enhygromyxa salina JCM 11769T (AB097590), and 91.3 to 91.5% with Plesiocystis 
pacifica JCM 11591T (AB083432). No information on the GC content of the bacterial 
genome has been found. Myxobacterium SMH-27-4 (AN: AB252740) was investigated 
for the production of secondary metabolites (108). This work led to the isolation and 
structure elucidation of two compounds of peptidic nature called miuraenamide A 34 and 
B 35. Two years later, the same research group published the structures of four 
additional derivatives, named miuraenamides C-F 36-39 (109).  
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Figure 4-13 Structures of miuraenamides A-F from P. miuraensis. 
X = Br Miuraenamide A  34 
X = I Miuraenamide B  35 
X = Cl Miuraenamide C  36 
 
Miuraenamide D 37 Miuraenamide E 38 
Miuraenamide F 39 
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The cyclic core structure of this compound class represents a halogenated depsipeptide 
with an additional polyketide-derived moiety. As in haliangicin, all miuraenamides, except 
E, contain a methoxyacrylate structural motif, which surely is important for the biological 
activity. For miuraenamide A 34 the absolute configuration was determined. Marfey´s 
method was employed to show that L-alanine and N-methyl D-tyrosine are present. 
Furthermore, after acid hydrolysis, methylation and application of modified Mosher´s 
method the absolute configuration at the oxygen-bearing C-9 was deduced as S. For 
miuraenamide F 39 the configuration at C-3 was found to be R, again using Mosher’s 
method.  For all the other chiral centers in compounds 35- 39 the authors conclude that 
they have the same configuration as determined for 34. Further work led to semi-
synthetic derivatives, which upon activity testing, revealed that the lactone moiety and 
the configuration of the methoxyacrylate partial structure are crucial for antifungal 
activity. The latter structural motif is well known from a range of antifungal compounds 
produced by fungi and myxobacteria, e.g. the strobilurins and the melithiazols (110, 111). 
Miuraenamide A 34 was assayed against various fungal, yeast and bacterial organisms. 
It showed a remarkable inhibitory effect toward the fungal phytopathogen Phytophthora 
capsici NBRC 8386 (MIC: 0.4 mg mL-1) and Candida rugosa AJ 14513 (MIC: 12.5 mg 
mL-1). No inhibitory effect on selected bacteria was detected. The mode of action is 
proposed to be similar to other antifungals with a methoxyacrylate partial structure, i.e. 
inhibition of the mitochondrial cytochrome bc1 complex. Additionally, Miuraenamide A 
was shown to act as actin filament stabilizer in HeLa cells (112). The activity of 
miuraenamide B 35 was not assessed due to the minute amounts of the metabolite 
available.To date, there is no genome sequence available for this organism. 
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4.9. The genus Pseudenhygromyxa 
Pseudenhygromyxa salsuginis is the latest example of a halotolerant myxobacterium,  
published in 2013 by Iizuka et al. (113). This organism was retrieved from mud samples 
of an estuarine marsh in a coastal area in Japan and termed SYR-2T. Even though it is 
able to grow in the absence of salt, optimal growth was shown to occur within a 
concentration range of 0.2 - 1.0 % NaCl (w/v) and pH values from 7.0 - 7.5 on CY-S agar 
(bacto casitone, bacto yeast extract) in a temperature range of 30-35 °C. After alignment 
of 16S rDNA sequences, Iizuka et al. (113) found that P. salsuginis SYR-2T showed 
96.5% and 96.0% identity to Enhygromyxa salina SHK-1T (NR_024807) and Plesiocystis 
pacifica SIR-1T (NR_024795), respectively. The G+C content is 69.7 mol%, and thus 
slightly higher than for various E. salina strains described above.  
To date, no reports on biological activities or any metabolites derived from P. salsuginis 
have been published. Nevertheless, the genetic proximity to E. salina and the fact that it 
belongs to the group of myxobacteria suggests that this organism may also possess a 
high potential as a producer of active molecules. To date, no genome sequence has 
been published.  
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 CHAPTER 2: Cyclopropane-containing fatty acids isolated from 
Labrenzia sp. strain 011 (Ostsee6) 
 
Marine microorganisms interact in a balanced coexistence, regulated to a high extent by 
chemicals, e.g. chemical warfare among fouling microorganisms and microbial 
symbionts or epibionts of a variety of macroscopic marine organisms with the capacity 
to produce antifouling compounds (23, 114, 115). Many of these interactions are 
dependent on secondary metabolism. Indeed, it has been established that epibiotic or 
symbiotic bacteria and metabolites produced by them play a major role in keeping their 
host healthy. A good example of these relations is the protective mechanism displayed 
by Alteromonas sp. I-2, which colonizes the embryos of the Caribbean shrimp Palaemon 
macrodactylus (116). This bacterium produces the antifungal agent 2,3-indolinedione, 
which prevents infection with the fungus Lagenidium callinectes, a frequent crustacean 
pathogen (116). In the same manner, embryos of the American lobster Homarus 
americanus were reported to be chemically protected against the same pathogen by the 
antifungal agent 4-hydroxyphenethyl alcohol, produced by the Gram-negative bacterium 
SG-76 (117).  
Within this context, species of the genus Labrenzia, previously classified Stappia (118) 
have been suggested to be protective agents of mollusks, e.g. Crassostrea virginica 
against Pseudoroseovarius crassostreae (also Aliiroseovarius crassostreae), the 
causative agent of roseovarius oyster disease (119–121). This pathogen negatively 
impacts the ecology of the marine environment and economic activities related to 
aquaculture of these marine organisms (122). A secondary metabolite-mediated 
mechanism is thought to be involved in the putative protective role of Labrenzia spp. 
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To date, there is only one report of a pederine-analgous compound isolated from the 
genus Labrenzia, i.e. Labrenzia sp. PHM005 (Fig 5-1) (25).  
 
Figure 5-1 This pederin analog is produced by the halophilic Labrenzia sp. PHM005 
(25). However, the ecological function of this interaction remains unknown. This molecule 
has been tested in vitro, showing cytotoxic activity against four different human cell lines: 
A549 (ATCC CCL-185) (lung carcinoma); HT-29 (ATCC HTB-38) (colon 
adenocarcinoma); MDA-MB-231 (ATCC HTB-26) (breast adenocarcinoma); and PSN-1 
(ATCC CRL-3211) (pancreas adenocarcinoma) (25). 
 
In this chapter, antimicrobial molecules produced by Labrenzia sp. strain 011 (Ostsee6) 
are described. These findings reinforce the idea that poses this bacterium as a biocontrol 
agent in the marine environment.   
5.1. Investigation of Labrenzia sp. strain 011 (Ostsee6) 
5.1.1. Isolation, taxonomy, and phenotype of Labrenzia sp. strain 011 
(Ostsee6) 
Labrenzia sp. strain 011 (Ostsee6) was retrieved as a free-living organism from a sample 
of marine sediment collected in August 2012 in the coastal area of Kronsgaard, 
Germany. The sample was air-dried and portions thereof were placed on WCX-ASW 
agar in Petri dishes. After 5 days of incubation at 30°C, creamy brownish colonies 
displaying gliding behavior on ASW-WCX agar were transferred to Petri dishes 
containing marine agar for isolation (Figure 5-2) (protocol described in section 3.2.1). 
Identification enabled by sequencing experiments revealed the identity of the isolate as 
a Labrenzia sp. strain 011 (Ostsee6).  
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Based on 16S rDNA alignments, it shares 99% identity with its closest relatives, namely 
Labrenzia alba strain 5OM6 (AN: NR_042378.1) and Labrenzia aggregata strain 
RMAR6-6 (AN: CP019630.1). 
 
 
 
 
 
 
 
Once the isolate was identified, in silico genomic mining experiments on annotated 
sequences of Labrenzia species were conducted, as well as on the draft genome of 
Labrenzia sp. strain 011 (Ostsee6). The analyses revealed that the latter and its selected 
relatives harbor gene clusters putatively involved in the production of secondary 
metabolites (Table 5-1).  
 
 
 
 
 
 
Figure 5-2 Colonies of Labrenzia sp. strain 011 (Ostsee6) on marine broth and marine 
agar respectively. This bacterium is motile by means of gliding, a trait often observed in 
heterotrophic organisms. The genus Labrenzia belongs to the -proteobacteria group, 
family Rhodobacteraceae. 
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Table 5-1 The most relevant findings from the annotated genomes of three species of 
Labrenzia and the draft genome of Labrenzia sp. strain 011 (Ostsee) are presented. 
Genomic mining analyses were run on these sequences using the antiSMASH software 
version 4.0.0 (42). These results were decisive to orient the research endeavors towards 
Labrenzia sp. strain 011 (Ostsee6) 
Organism 
 
Labrenzia sp. 
011 (Ostsee6) 
 
L. alexandri 
DFL11 
 
Labrenzia sp. 
CP4 
 
L. alba 
CECT7551 
Genome size 
(Mb) 5.1 5.5 6.1 5.9 
Accession 
number 
Not yet published NZ_ACCU00000000.1 NZ_CP011927.1 NZ_CXTY00000000.1 
GC % 60.3 56.4 58.9 53.8 
% of genome 
involved in 
secondary 
metabolisma 
1.51 2.05 2.06 1.32 
Scaffolds - 6 - 41 
Total 
number of 
clusters 
3 4 5 3 
Type I PKS 1 1 1 1 
NRPS 0 0 1 0 
Terpene 1 2 2 0 
Bacteriocin 1 1 1 1 
Carotenoid 0 0 0 1 
aTotal bases of all secondary metabolite gene clusters detected by antiSMASH divided by 
number of bases in the genome (Genome size).      
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5.1.2. Unveiling the antimicrobial capabilities of Labrenzia sp. strain 011 
(Ostsee6) 
Cultivation was conducted according to sections 3.2.6 and 3.3.2. A crude extract was 
obtained by liquid-liquid extraction using ethyl acetate as organic solvent as described in 
section 3.3.1. The crude extract was fractionated as shown in section 3.3.3 (VLC). The 
fractions obtained from the VLC column were evaporated to dryness and resuspended 
in methanol to a final concentration of 1 mg/mL. Samples of 50 L of each fraction 
equivalent to 50 g were used for antimicrobial testing on disc diffusion tests (Table 5-
2). 
Table 5-2 Disc diffusion tests were applied for initial antimicrobial screening, using 50 
g of the solvent-fractionated extract of Labrenzia sp. strain 011 (Ostsee6). Codes in the 
table are FR1 = DCM fraction, FR2 = EtOAC fraction, FR3 = Acetone fraction, FR4 = 
MeOH fraction. T.i. = total inhibition, W.i. = weak inhibition. In these experiments, FR2 
showed growth inhibition of a range of test microorganisms. Meanwhile, FR1, 3 and 4, 
did not show antimicrobial activity. 
Test Organism Test organism 
Diameter of 
inhibition zone of 
fraction FR2  
Bacillus megaterium DSM 32 Bacterium 3 mm (T.i.) 
Escherichia coli DSM 498 Bacterium <1 mm (W.i.) 
Eurotium rubrum DSM 62631 Fungus 2 mm (T.i.) 
Microbotryum violaceum MB#110229 Fungus 4 mm (T.i.) 
Mycotypha microspora MB#271115 Fungus <1 mm (W.i.) 
 
Fraction 2 (FR2), eluted with ethyl acetate showed the most promising results in terms 
of microbial growth inhibition and a promising pattern in the 1H-NMR spectrum (spectrum 
not shown). This fraction oriented the research efforts intended to identify the substances 
responsible for the antimicrobial activity described in the upcoming sections.  
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5.1.3. Metabolites isolated from Labrenzia sp. strain 011 (Ostsee6) 
5.1.3.1. Large-scale cultivation of bacterium and isolation of metabolites  
Cultures (12 L) were produced according to 3.2.6 in the experimental section. 
Metabolites were retrieved from marine broth according to section 3.3.2 utilizing 20 g of 
sepabeads 207/L of marine broth. After ten days of cultivation, the sepabeads were 
extracted with acetone for 24 hours as described in section 3.3.2. The crude extract 
obtained was 2.9 g of an oily dark residue, which was dissolved in 50 mL of aqueous 
methanol 60% and extracted three times with 60 mL of dichloromethane. The lipophilic 
phase was evaporated to dryness and yielded 617.9 mg of a dark oily extract. This 
extract was separated on a flash chromatography device. The fraction of interest (21.2 
mg) was obtained by a linear gradient (0-3 min acetone/petroleum ether 0:100, 3-9 min 
up to 25% acetone, 9-10 min up to 100% acetone, ≈ 20 min 100% acetone at a constant 
flow rate of 30 mL/min), using a Reveleris silica column of 12 g (12 mg – 2.4 g sample 
load capacity, 12 m). This fraction was collected between minute 5 and 6, evaporated 
under vacuum and resuspended in acetone. It was further fractionated by semi-
preparative HPLC using a linear gradient (0-5 min acetonitrile/water 50:50, 5-20 minutes 
up to 100% acetonitrile, ≈ 50 min 100% acetonitrile, containing 0.01 M H3PO4 each 
solvent at a constant flow rate of 1 mL/min). The column YMC-triart C18 / S-5m /12 nm 
(250 x 4.6 mm I.D) was employed for this step. Two oily colorless substances to [(1), 1 
mg; (2), 6 mg] were obtained. Their retention time was respectively 22 (100% 
acetonitrile) and 17 min (90% acetonitrile) (Figures 9-1, 9-2 and 9-3 in the appendix).  
5.1.4. Structure elucidation of metabolites isolated from Labrenzia sp. strain 
011 (Ostsee6) 
Two cyclopropane-containing fatty acids were isolated (CYPFA) (1, 2, Figure 5-3). The 
structures of (1) and (2) were established by extensive NMR analyses (1H, 13C, COSY 
and HMBC, Table 5-3 and 5-4 respectively).  
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All chemical shifts were measured relative to the chloroform peak (7.26 ppm for 1H-NMR, 
77.16 ppm for 13C-NMR).  
 cis - 4 - (2 - hexylcyclopropyl) - butanoic acid (1): the 13C-NMR spectrum showed 12 
resonances between 10 to 35 ppm attributable to an aliphatic compound (see Appendix, 
Figure 9-7). Furthermore, the resonance at 178.1 ppm suggested the presence of a 
carboxylic group (see Appendix, Figure 9-7). 1H-13C HMBC showed correlations from the 
-methylene signal of H-2 ( 2.40 ppm, t, J = 7.6 Hz, 2H) to the carboxyl signal C-1 (C 
178.1 ppm, C) and C-8 (C 25.2 ppm, CH2).  - methylene signal of H-8 ( 1.75, p, J = 
7.6 Hz, 2H) showed a mutual 1H-1H COSY correlation with splitted methylene signals 
of H-7 (1.46 ppm (a), m, H;  1.22 ppm (b), m, H). Further analysis of the 1H-1H COSY 
correlations showed that the splitted high-field methylene signals in the 1H-NMR 
spectrum (see Appendix, Figure 9-6) H-13a/H-13b (-0.30 ppm (b), q, J = 4.6 Hz, H; 
 0.63 ppm (a), m, H) were coupled with methine signals H-10 ( 0.66 ppm, m, H) and 
H-11 ( 0.68 ppm, m, H). Finally, 1H-13C HMBC analysis showed a correlation of H-
13a/H-13b with methine signals C-10 (C 15.2 ppm, CH) and C-11 (C 15.7 ppm, CH). 
The 1H-1H COSY and 1H-13C HMBC coupling patterns were assigned to a 1, 2 - 
disubstituted cyclopropane ring with three methylene groups between the ring and the 
carboxylic moiety. Five remaining methylene groups and one methyl group, namely H-3 
(H 1.27, m, 2H), H-4 (H 1.35, m, 2H), H-5 (H 1.27, m, 2H), H-6 (H 1.35, m, 2H), H-9 
(H 1.28, m, 2H) and 12-H (H 0.88, t, J = 6.8 Hz, 3H) were assigned as shown in Table 
5-3. The chemical shift of H-13b (-0.30 ppm) suggested the cis stereochemistry of 
the three-membered ring, confirmed by comparison of 1H-NMR chemical shifts of H-10, 
H-11, and H-13 with related reference compounds (123). 
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cis - 2 - (2 - hexylcyclopropyl) - acetic acid (2): the 13C-NMR spectrum showed 10 
resonance signals between 10 and 35 ppm (see Appendix, Figure 9-9) attributable to an 
aliphatic compound, suggesting a high similarity to (1). The 13C-NMR signal at 180.2 ppm 
suggested the presence of the carboxylic moiety (see Appendix, Figure 9-9). 1H-13C 
HMBC correlations were observed from the splitted -methylene signals of H-2 ( 2.42 
ppm (a), dd, J = 6.9, 16 Hz, H; 2.29 ppm (b), dd, J = 7.8, 16 Hz, H) to C-1 (C 180.2 
ppm, C). The splitted high-field signals in the 1H-NMR spectrum (see Appendix, Figure 
9-8) H-11a/H-11b (-0.13 ppm (b), q, J = 5.0 Hz, H;  0.75 ppm (a), dq, J = 8.4, 5.0, 
H) were coupled with methine protons H-8 ( 0.81 ppm, m, H) and H-10 ( 1.10 ppm, 
m, H,) according to 1H-1H COSY analysis. Correlations detected in 1H-13C HMBC of H-
11a/H-11b with methine signals C-8 (C 15.5 ppm, CH) and C-10 (C 11.1 ppm, CH) 
suggested a cyclopropane ring configuration similar to (1). Five remaining methylene 
groups and one methyl group, namely H-3 (H 1.26, m, 2H), H-4 (H 1.37, m, 2H), H-5 
(H 1.29, m, 2H), H-6 (H 1.35, m, 2H) H-7 (H 1.29, m, 2H) and 9-H (H 0.88, t, J = 7.3 
Hz, 3H) were assigned as shown in Table 5-4. The coupling patterns were assigned to 
a 1, 2-disubstituted cyclopropane ring with only one methylene group between the ring 
and the carboxylic moiety. The chemical shift of H-11b (-0.13 ppm) suggested the cis 
stereochemistry of the three-membered ring, confirmed by comparison of 1H-NMR 
chemical shifts of H-8, H-10 and H-11 with related reference compounds (123).  
The lack of chromophores was evident from UV-data [(1) max = 200 nm, (2) max = 206 
nm]. Structures were confirmed by HRESIMS measurements shown in 5.1.5 
(chromatograms in appendix, Figure 9-4 and 9-5). Additionally, NMR spectroscopic data 
of compound (2) were equivalent to cis - cascarillic acid, an analogous structure to (2) 
(124–126) (see Appendix, Table 9-1). cis - cascarillic acid is known to occur in minute 
amounts in the acidic fraction of the essential oil of Croton eluteria, a medicinal shrub 
(124).  
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The main component of this fraction is trans - cascarillic acid (3, [α]𝐷 = -8.9, in CHCl3, 
Figure 5-3)(124).  
The rotatory power of CYPFAs measured in our laboratory[α]𝐷
20. The results of these 
measurements are shown in section 5.1.5. This is to the best of our knowledge, the first 
description of compound (1).  
5.1.5. Spectroscopic characterization of Labrenzia sp. strain 011 (Ostsee6) 
metabolites  
Compound 1: cis - 4 - (2 - hexylcyclopropyl) - butanoic acid; colorless oil; [α]𝐷
20 -15 (c 
0.1, CHCl3); UV (acetonitrile) λmax (ε) 207 nm (2366.42 M-1cm-1); 1H- and 13C-NMR (Table 
5-3); (+) HRESIMS m/z 235.1660 [M+Na]+ (calculated for C13H23O2Na, 235.1629). 
Compound 2: cis - 2 - (2 - hexylcyclopropyl) - acetic acid; colorless oil; [α]𝐷
20 -1 (c 0.1, 
CHCl3); UV (acetonitrile) λmax (ε) 200 nm (1071.12 M-1cm-1); 1H- and 13C-NMR (Table 5-
4); (+) HRESIMS m/z 207.1308 [M+Na]+ (calculated for C11H19O2Na, 207.1316). 
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Figure 5-3 Proposed structures for (1) and (2), cyclopropane fatty acids produced by the 
Labrenzia sp. strain 011 (Ostsee6).The cis (Hc) and trans (Ht) protons of the methylene 
group 13C-CH2 are shown. The absolute configuration of trans-cascarillic acid ([(1S,2R)-
2-hexylcycloprop-1-yl]-acetic acid) (3) is presented as depicted by (126). 
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Table 5-3 1D and 2D NMR spectroscopic data (300 MHz, CDCl3) of compound 1.  
 
Position C, mult [ppm] H (J in Hz) [ppm] 1H-1H COSY  1H-13C HMBC 
1 178.1, C - -  
2 33.5, CH2 2.40, t (7.6) 8 1, 7, 8 
3 31.9, CH2 1.27, m   
4 30.1, CH2 1.35, m   
5 29.3, CH2 1.25, m   
6 28.7, CH2 1.35, m   
7 28.0, CH2 
a:1.46, m 
b: 1.22, m 
7b, 8, 10 
7a, 8, 10 
10 
10 
8 25.2, CH2 1.75, p (7.6) 2, 7 1, 2, 7, 10 
9 22.7, CH2 1.28, m 12  
10 15.2, CH 0.66, m 7a/b, 13a/b  
11 15.7, CH 0.68, m 6  
12 14.1, CH3 0.88, t (6.8) 9 3, 9 
13 10.9, CH2 
at: 0.63, m 
bc: -0.30, q (4.6) 
10, 11, 13b 
10, 11, 13a 
6, 7, 10, 11 
6, 7, 10, 11 
      ccis-configured proton; ttrans-configured proton 
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Figure 5-4 Graphic representation of 1H-1H COSY correlations of (1) detected in NMR 
spectroscopic studies. Correlations between H2-13a(c)/b(t) with H1-10 and H1-11 were 
useful to determine the presence of a 1,2-disubstituted cyclopropane ring.         
 
 
Figure 5-5 Graphic representation of 1H-13C HMBC correlations of (1) detected in NMR 
spectroscopic studies. The selected correlations were crucial to establish the number of 
carbons between the carboxylic moiety and the cyclopropane ring.          
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Table 5-4 1D and 2D NMR spectroscopic data (300 MHz, CDCl3) of compound 2.  
 
Position 
C, mult 
[ppm] 
H (J in Hz) [ppm] 1H-1H COSY  1H-13C HMBC  
1 180.2, C - - - 
2 33.7, CH2 
a: 2.42, dd (6.9, 16.0) 
b: 2.29, dd (7.8, 16.0) 
2b, 10 
2a, 10 
1, 8, 10, 11 
1, 8, 10, 11 
3 31.9, CH2 1.26, m   
4 29.8, CH2 1.37, m   
5 29.2, CH2 1.29, m   
6 28.8, CH2 1.35, m   
7 22.6, CH2 1.29, m 9  
8 15.5, CH 0.81, m 10, 11a/b  
9 14.1, CH3 0.88, t (7.3) 7 3, 7 
10 11.1, CH 1.10, m 2, 8, 11a/b  
11 10.8, CH2 
at: 0.75, dq (8.4, 5.0) 
bc: -0.13, q (5.0) 
8, 10, 11b 
8, 10, 11a 
2, 4, 8, 10 
2, 4, 8, 10 
     ccis-configured proton; ttrans-configured proton 
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Figure 5-6 Graphic representation of 1H-1H COSY correlations of (2) detected in NMR 
spectroscopic studies. Correlations between H2-11a(c)/b(t) with H1-10 and H1-8 were 
useful to determine the presence of a 1,2-disubstituted cyclopropane ring.         
 
 
Figure 5-7 Graphic representation of 1H-13C HMBC correlations of (2) detected in NMR 
spectroscopic studies. The selected correlation was crucial to establish that, unlike 
compound (1), compound (2) presents only one carbon atom between the carboxylic 
moiety and the cyclopropane ring.            
 
5.1.6. Bioactivity assessment 
5.1.6.1. Antimicrobial properties 
Antimicrobial capacities of (1) and (2) were assessed revealing remarkable growth 
inhibition of a range of bacterial and fungal organisms in disc diffusion tests (DDT) (Table 
5-5). Furthermore, cytotoxic activity of compound (2) was tested, displaying no effect 
against the human cell line selected for this purpose (Table 5-5).  
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Table 5-5 Summary of bioactivities attributed to the compounds (1) and (2) in disc 
diffusion and cytotoxicity testing. For the antimicrobial evaluation, 50 g of each 
compound and positive control were utilized. Values presented are inhibition zones in 
mm. Different concentrations at a micromolar level for the cytotoxicity assay (max. 50 
M). Streptomycin was used as the antibacterial positive control; meanwhile, miconazole 
as the antifungal positive control. Etoposide worked as the positive control in cytotoxicity 
test.  
Antibacterial activity 
Organism  1 2 Streptomycin (+) 
Escherichia coli DSM 498 2 3 6 
Bacillus megaterium DSM 32 NA 10 9 
Pseudoroseovarius crassostreae DSM 
16950T 
5 5 6 
Antifungal activity 
Organism 1 2 Miconazole (+) 
Eurotium rubrum DSM 62631 NA 10 8.5 
Mycotypha microspora MB#271115 3 6 9 
Microbotryum violaceum MB#110229 8 10 6 
Citotoxic activity 
HEK293 embryonic kidney cell line 
2 Etoposide (+) 
>50 M 
50 M 40%  cell 
viability 
NA: no activity 
Due to efficient growth inhibition exhibited by compound (2), it was selected to evaluate 
its antimicrobial properties against pathogens of human concern (Table 5-6). 
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Table 5-6 Disc diffusion test panel for the evaluation of compound (2) against multidrug-
resistant bacteria. The values shown correspond to inhibition zone in mm. The amount 
of substance evaluated was 3 g. No positive controls for the selected organism were 
available. DMSO was used as negative control. These experiments were kindly 
conducted by MTA Michaele Josten at the Institute for Medical Microbiology of the 
University of Bonn.   
Organism (2) 
Echerichia coli I-11276b 2 
Echerichia coli O-19592 2 
Klebsiella pneumoniae subsp. ozeanae I-10910 2 
Listeria welchimeri DSM 20650 2 
MRSA  LT-1338 2 
MRSA LT-1334 2 
MSSA 5185 2 
MSSA I-11574 2 
Staphylococcus aureus 133 3 
Staphylococcus aureus SG 511 3 
Stenotrophomonas maltophilia I-10717 2 
 
5.1.6.2. Effect of compounds 1 and 2 at the Gi protein-coupled receptor GPCR84. 
The G protein-coupled receptor (GPCR) 84 (GPR84) is a pro-inflammatory Gi protein-
coupled class A GPCR which is highly expressed in the bone marrow, lung tissue, 
microglial cells, peripheral leucocytes (127–130). It has been demonstrated that 
medium-chain fatty acids (9-14 carbon atoms) exert agonistic-mediated pro-
inflammatory activities promoted by this receptor (125, 130, 129, 128). Wang et al 
demonstrated that undecanoic acid (11C) induced this effect (128). Later research 
concluded that 2- and 3- hydroxylated undecanoic acid are more potent agonists than 
the non-hydroxylated molecule (130). This particular fact leads us to theorize that the 
carboxylic acid end, spanning the cyclopropyl moieties adjacent to the carbon 4 of (1) 
and carbon 2 of (2), may be crucial for the affinity and the interaction with this receptor.  
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To date, the isolated fatty acid derivatives (1) and (2) were investigated in radioligand 
binding assays at the human GPR84 receptor expressed in Chinse Ovarian Hamster 
cells. The experiments were kindly conducted in collaborative work in the research unit 
under the responsibility of Prof. Dr. Christa Müller and supervised by Dr. Meryem Köse. 
Their work produced the following results: 
Table 5-7 In vitro potencies of fatty acid derivatives (1) and (2) at GPR84 expressed in 
Chinese hamster ovary cells (CHO).   
  
  
         
 
Compound 
Human GPRC84 
Binding Assay cAMP assaya -arrestin assay 
Ki ± SEM (µM) 
vs. [3H]PSB-1584 
(or % inhibition 
± SEM at 100 µM) 
   (n=3) 
EC50 ± SEM (µM) 
(or % receptor 
activation ± SEM 
at 100 µM) 
   (n=3) 
EC50 ± SEM (µM) 
(or % receptor 
activation ± SEM at 
30 µM) [efficacy]b 
   (n=5) 
Decanoic acid 3.18 ± 0.514 
7.42 ±0.40 
[100%]5 
6.08 ± 0.36 [92%]5 
Dodecanoic 
acid 
3.62 ± 0.494 8.87 ± 0.754 2.84 ± 0.314c 
1 > 100 (11%) >> 100 (0%) > 30 (17 %) 
2 13.3 ± 2.0 (88%) > 100 (24%) 0.114 ± 0.060 [54%] 
aInhibition of forskolin- (10 µM) -induced decrease in cAMP accumulation 
bEfficacy (Emax) relative to the maximal effect of the full agonist embelin (10 µM) (=100%) 
cn=3 
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Compound (2) showed an affinity for GPR84 with a Ki value of 13.3 µM (Table 5-7, Figure 
5-8), which is in about the same range (about 4-fold higher) as that of the physiological 
agonists decanoic acid (capric acid) and dodecanoic acid (lauric acid). Compound (1) 
did not show any affinity for GPR84 at concentrations up to 100 µM.  
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Figure 5-8 Competition binding experiments at membrane preparations of CHO 
cells recombinantly expressing the human GPR84. The experiments were performed 
at 25 °C (150 min) using 2 nM [3H]PSB-1584 and 10 μg protein/vial in 50 mM TRIS buffer, 
pH 7.4, 10 mM MgCl2, 0.05 % fatty acid free BSA. A Ki value of 13.3 ± 2.0 µM was 
calculated for compound (2) and a Ki value of 3.18 ± 0.51 µM for the known agonist 
decanoic acid. Data points represent means ± SEM from 3 independent experiments, 
each performed in duplicates. 
 
GPR84 agonistic properties were evaluated in two different assays: (1) cAMP 
accumulation assays determining the compounds’ potency to inhibit forskolin-induced 
cAMP accumulation in Chinese hamster ovary (CHO) cells stably expressing the Gi 
protein-coupled human GPR84, and (2) -arrestin recruitment assays using the enzyme 
complementation technology. 
Compound (1) was inactive in both assays in agreement with results obtained in 
radioligand binding experiments. Compound (2) did neither induce nor block Gi-mediated 
signalling; however, it showed a concentration-dependent activation of -arrestin 
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recruitment with an EC50 value of 114 nM being 53-fold more potent than decanoic acid 
(EC50 = 6.08 µM) and 25-fold more potent than dodecanoic acid (EC50 = 2.84 µM) in that 
assay (Table 5-7, Figure 5-9). The efficacy was determined to be 54 % compared to the 
full agonist embelin. This indicates that compound (2) is a partial agonist of GPR84 
biased towards -arrestin recruitment.  
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Figure 5-9 Concentration-response curve of (2) determined in β-arrestin assays 
using the -galactosidase complementation technology. The maximal luminescence 
induced by the full agonist embelin (10 µM) was defined as 100 %. The buffer control 
was defined as 0 %. An EC50 value of 114 ± 60 nM was calculated for (2). Mean values 
± SEM from 5 independent experiments performed in duplicates are shown. 
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 CHAPTER 3: Bioactivity assessment of bacteria isolated from the 
German North Sea  
 
6.1. Background  
Supporting our efforts to find bioactive compounds from microbial producers, the 
research group of Prof. Dr. Thorsten Brinkoff (Oldenburg University) kindly provided our 
group with marine environmental samples collected in the German coastal area of 
Neuharlingersiel, from which we isolated bacterial strains.  
Bacteria were isolated applying the protocol described in section 3.2.1. The most 
promising organisms in terms of potential production of bioactive metabolites are listed 
in Table 6-1 together with some of their most relevant phenotypic traits. Preliminary strain 
identification was done by 16S rDNA Sanger sequencing experiments. The 
corresponding sequences are shown in the appendix (A9.2 - A9.4).  
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Table 6-1 Phenotypic profiling of the bacteria isolated from marine environmental 
samples. The nomenclature of each organism (Siel #L) was randomly assigned and hold 
no implications of any kind with the experimental observations.  
Isolate Siel 3m Siel 4n Siel 7n Siel 8n 
16S rDNA-
based identity 
94 % 
Uncultured 
bacterium (AN: 
GU118051) 
97 % 
Uncultured 
bacterium (AN: 
GQ867431) 
97 % 
Lysobacter sp. 
(AN: 
JQ716253) 
99 % 
Myxococcus 
xanthus (AN: 
NR_074873) 
Origin Clam shell Sediment Sediment Sediment 
Lytic activity Yeast Yeast, bacteria Yeast, bacteria Yeast, bacteria 
Approximate 
length (m) 
15-20 3-7 5-10 5-10 
Temperature 
growth range 
(°C) 
4-37 20-37 20-37 20-37 
 
The following phenotypic traits are common for the 4 isolates: Gram-negative staining, 
rod shape, halotolerance, aerobic metabolism, and gliding motility. Isolates Siel 4n, 7n 
and 8n were capable to lyse E. coli bacterial spots (section 3.2.1) and S. cerevisiae. The 
latter feature was observed in broth ASW-VY/4. The broth is turbid due to the S. 
cerevisiae suspension, thus its clearance after bacterial growth was taken as positive 
lytic activity on yeast. Siel 3m lysed exclusively these cells.   
Sequencing results of 16S rDNA sequences allowed preliminary identification of the 
isolates. Additionally, Siel 8n exhibited the typical yellow pigmentation and fruiting body 
formation features of the genus Myxococcus (48, 50), further confirming the sequencing 
results.   
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6.1.1. Biological assessment of the bacterial isolates    
In order to confirm the first observations in terms of bioactivity, and further characterize 
the organisms, a deeper biochemical profiling was done and a bioactivity-screening 
panel was designed to test the metabolites produced by the isolated bacteria (131). Such 
work is supplementary to this doctoral thesis and includes detailed descriptions of 
methods and materials employed in the evaluation of the isolates.  
The lytic behavior displayed by the organisms may be a reflection of predatory habits 
and presumably, of potential production of chemical bioactive substances. Hereby we 
present the biochemical profile of the isolates and lytic behavior on cyanobacteria, E. coli 
and S. cereviseae assays (Table 6-2).  
Table 6-2 Summary of bioactivities and phenotypic traits of the bacteria isolated from 
environmental samples.  
Isolate Siel 3m Siel 4n Siel 7n Siel 8n 
Fischerella ambigua lysis - + - - 
Nostoc sp. lysis - + - + 
Nostoc insulare lysis - - - - 
Oscillatoria sp. lysis - + - + 
Tychonema sp. lysis - - - - 
E. coli lysis - + + + 
S. cerevisiae lysis + + + + 
Haemolysis    (-) 
Chitosanase - - - - 
Cellulase - - - - 
Agarase + - - - 
Amylase - - + - 
Gelatinase + + - + 
Caseinase - - + + 
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β-galactosidase + (g) + (g) + (-) 
Catalas + + + + 
+ = Lysis or enzyme activity; – = No lysis or no enzyme activity; (–) = No growth; β = β-haemolytic; 
 = -haemolytic; (g) = Gas production 
 
6.1.1.1. Production of bacterial crude extracts 
Bacteria were grown in ASW-VY/4 and casitone broth. Extracts of each culture were 
obtained by liquid-liquid extraction using ethyl acetate as described in 3.3.1. Extracts 
were evaluated in agar diffusion tests (Table 6-3).  
Table 6-3 Disc diffusion test of extracts obtained from the bacterial culture. A volume 
equivalent to 50 g of each extract was used for the evaluation. Values shown 
correspond to mm of growth inhibition on the test strains. Ampicillin and miconazole (50 
g) were used as positive control, respectively against bacteria and fungi. 
Antibacterial activity 
Organism 
Siel 
3m 
Siel 
4n 
Siel 
7n 
Siel 
8n 
Ampicillin (+) 
Escherichia coli DSM 498 NA NA NA NA 13 
Bacillus megaterium DSM 32 3 NA NA NA 15 
Antifungal activity 
Organism 
Siel 
3m 
Siel 
4n 
Siel 
7n 
Siel 
8n 
Miconazole 
(+) 
Eurotium rubrum DSM 62631 NA NA NA NA 8 
Mycotypha microspora  
(this study ) 
NA NA NA NA 9 
Microbotrium violaceum  
(this study) 
2.5 NA NA NA 9 
NA: no activity 
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 SUMMARY 
 
Bacteria are the source of many biotechnologically produced drugs, e.g. the antibacterial 
antibiotics daptomycin and vancomycin, the antifungal antibiotic amphotericin B, and 
chemotherapeutic anticancer agents, e.g. doxorubicin. For decades, such bacteria were 
isolated from terrestrial sources, above all from soil samples. Thus, the 
immunosuppressive drug tacrolimus, biosynthesized by the bacterium Streptomyces 
tsukubaensis was obtained from a soil sample collected in Japan, and is today 
administrated to patients with organ transplants with the aim to decrease the risk of 
immune-mediated rejection of the organs received. It has been proposed that 
microorganisms produce such secondary metabolites for ecological purposes, e.g. to 
weaken or kill competitors for nutrients.  
The current project focuses on marine-derived bacteria as a novel source of compounds 
with a presumably high degree of structural novelty. Indeed, marine actinomycetes were 
found to be producers of highly bioactive compounds, e.g. Salinispora tropica as the 
source of salinosporamide A, a selective proteasome inhibitor currently undergoing 
clinical studies as anticancer drug. The objective of the current study is to assess the 
biosynthetic capabilities of marine-derived bacteria, either through a genome-mining 
approach and/or through the isolation of bioactive products. 
The first group of bacteria investigated was marine myxobacteria, an overlooked source 
of bioactive compounds. Interestingly, some of the chemistry known from these bacteria, 
e.g. salimabromide from Enhygromyxa salina SWB007 was unprecedented. To date, 
many bacterial genomes are publicly available. Among such genomes are also some 
from marine myxobacteria. Using bioinformatic tools like antiSMASH, genomes of marine 
myxobacteria, namely Haliangium, Enhygromyxa, Myxobacterium SMH-27-4 
(Paraliomyxa), Plesiocystis and Pseudenhygromyxa were analysed. These works 
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revealed numerous putative gene clusters encoding enzymes for secondary metabolites 
in each strain analysed. Among the most relevant findings are the 38 biosynthetic gene 
clusters detected in Enhygromyxa salina DSM 15201, 28 gene clusters in Plesiocystis 
pacifica SIR 1, and 25 in Haliangium ochraceum DSM 14365. Mostly, the gene clusters 
detected correspond to hybrids of polyketide synthase and non-ribosomal peptides. 
Additionally, the putative gene cluster encoding the cytotoxic drug haliangicin 
(cytotoxicity, HeLa-S3 cell line, IC50 = 12 M) produced by H. ochraceum was envisioned. 
The prospective research possibilities offered by these organisms concerning the 
potential secondary metabolite production is vindicated. 
Five bacterial strains were isolated from German coastal areas. The most remarkable 
activities were shown by one unclassified isolate labeled Siel 3m and Labrenzia sp. strain 
011 (Ostsee6). These bacteria were respectively isolated from a seashell collected in 
Neuharlingersiel, and marine sediment retrieved from the shallows of Kronsgaard, 
Germany. 
Extracts of the bacterium Siel 3m showed growth inhibition of bacteria and fungi in disc 
diffusion tests (mm of inhibition at 50 g). Susceptible organisms were the bacterium 
Bacillus megaterium DSM 32 (3 mm) and the fungus Microbotrium violaceum (2.5 mm). 
Additionally, the growing bacterium Siel 3m displayed lytic activity against 
Saccharomyces cereviseae. To date, no metabolites responsible for these activities 
have been identified. 
Concerning Labrenzia sp. strain 011 (Ostsee6), experiments to identify metabolites of 
biological interest were conducted. Antimicrobial-oriented evaluation of bacterial extracts 
showed growth inhibition of fungi and bacteria. Fractionation and purification of the 
extracts yielded two metabolites of lipid nature, namely (1) cis - 4 - (2 - hexylcyclopropyl) 
- butanoic acid and (2) cis - 2 - (2 - hexylcyclopropyl) - acetic acid; (1) exhibiting a novel 
structure.  
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The structures were deduced by extensive 1H-, 13C- and 2D-NMR analyses. 
Interpretation of NMR spectra revealed aliphatic compounds, showing resonance signals 
in the upfield regions of the 1H-NMR spectrum with negative ppm values, consistent with 
the typical resonances of protons of cyclopropane moieties. NMR studies together with 
UPLC-HRMS confirmed the structures of the compounds presented below: 
  
 
cis - 4 - (2 - hexylcyclopropyl) - butanoic acid (1) 
 
cis - 2 - (2 - hexylcyclopropyl) - acetic acid (2) 
 
Antimicrobial activities of (1) and (2) were assessed revealing remarkable growth 
suppression of a range of bacteria and fungi. The activity spectrum of compound (2) 
assessed in disc diffusion tests included bacterial pathogens, e.g. methicillin-resistant 
Staphylococcus aureus strain LT-1338 (2 mm diameter inhibition, 3 g/disc). 
It has been proposed that species of the genus Labrenzia play important ecological roles 
in the marine habitat. This notion originates from previous research works where it was 
observed that colonization of the oyster Crassostrea virginica by species of the genus 
Labrenzia prevented infection by the bacterial oyster pathogen Pseudoroseovarius 
crassostreae. In the present work, the antimicrobial compounds (1) and (2) isolated from 
Labrenzia sp. strain 011 (Ostsee6) were tested against P. crassostreae strain DSM 
16950.  
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These experiments revealed remarkable growth inhibition of P. crassostreae DSM 16950 
in disc diffusion tests (1 and 2, 5 mm diameter inhibition; streptomycin as positive control, 
6 mm diameter inhibition, 50 g/disc). These results add up to the aforementioned notion 
that posed bacteria of the genus Labrenzia as biocotrol agents in the marine 
environment.  
Due to similarities among compounds (1) and (2) with medium-chain fatty acids, both 
compounds were evaluated as ligands at the medium-chain fatty acid receptor GPCR 84 
(collaboration with Prof. Dr. Christa Müller), which is upregulated in inflammatory 
processes. In this context, it is of interest that compounds similar to (1) and (2) were also 
isolated from Croton eleuteria, a plant whose aqueous extracts have been used as 
inhalants in folk medicine to palliate the inflammatory symptoms of respiratory ailments. 
Compound (1) did not show affinity towards this receptor (Ki > 100 M), unlike compound 
(2), which indeed showed affinity (Ki = 13.3 ± 2.0 M). Analyses of the latter interaction 
revealed that compound (2) is a partial agonist at this receptor biased to -arrestin 
accumulation (cAMP assay, EC50 > 100 M; -arrestin assay, EC50 = 0.114 ± 0.06 M). 
These results suggest that (2) may affect inflammatory processes in vivo. 
In conclusion, this work vindicates unusual bacterial sources as efficient producers of 
bioactive metabolites with the potential to become lead compounds. Interestingly, 
genomic explorations revealed that microorganisms like myxobacteria are an 
underexplored source of promising compounds, comparing the number of gene clusters 
harbored in their genomes and the compounds isolated hitherto. Furthermore, 
substances isolated from the halophilic bacterium Labrenzia sp. strain 011 (Ostsee6) 
showed that the growth of resistant bacterial pathogens can be inhibited, e.g. Escherichia 
coli I-11276b, Escherichia coli O-19592, MRSA LT-1338, MRSA LT-1334, 
Staphylococcus aureus SG 511. Altogether, genomic and chemical studies performed 
during the current project point towards a rich resource of chemical structures that may 
be investigated in the search for new bioactive molecules.      
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 DISCUSSION AND CONCLUSIONS  
 
Bacteria produce many of the antibiotics currently used, e.g. the antibacterial 
daptomycin, vancomycin, the antifungal amfotericin B, and drugs used to treat cancer, 
e.g doxorubicin (132–135). For decades, such bacteria were isolated from terrestrial 
sources, above all soil samples. It has been proposed that microorganisms produce this 
class of compounds as secondary metabolites for ecological purposes, e.g weaken or 
kill competitors for nutrients and living preys in their environments.  
The current project focuses on marine-derived bacteria as a novel source of compounds 
with a high degree of structural novelty. The objective is to discover new compounds in 
order to tackle the phenomenon of antimicrobial resistance.   
The marine bacteria investigated in this work are, on one hand, myxobacteria, some of 
them marine obligates and, on the other hand the strictly halophilic -proteobacterium 
Labrenzia sp. strain 011 (Ostsee6). The myxobacteria were analysed in silico and L. 
aggregata experimentaly, yielding two bioactive molecules (1 and 2) with antimicrobial 
and possibly, anti-inflammatory properties which will be discussed in the following 
sections.      
8.1. Marine-derived myxobacteria 
Geographically, halophilic and halotolerant myxobacteria are widely distributed as 
evidenced by some of the bacterial isolates described in chapter 4, originating, e.g. from 
German, Japanese and US American marine environments. This observation is 
supported by the investigation of myxobacteria-enriched libraries of 16S rRNA gene 
sequences revealing myxobacteria-related sequences in mud samples taken around 
Japan (136). The latter sequences were phylogeographically clearly distinct from those 
of terrestrial myxobacteria (136).  
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A further report also states that myxobacteria capable of thriving in ocean-like conditions 
exhibit a worldwide distribution (137).  
The quantitative presence of myxobacteria in marine environments can hardly be judged. 
Based on the isolation success one may suggest that the frequency is much lower (e.g. 
only 6 isolates from 90 coastal samples (57, 59)) than in terrestrial habitats, but this may 
simply represent the less-than-perfect isolation and cultivation conditions used today. 
Indeed, the currently applied isolation protocols for marine myxobacteria are only slightly 
altered in terms of the addition of sea salt, when compared to those for terrestrial strains, 
e.g. terrestrial Escherichia coli is still used as prey. In addition, it is difficult to recognize 
marine myxobacterial colonies after isolation, because their morphological features may 
deviate from the ones of terrestrial strains. Thus, in order to use marine-derived 
myxobacteria as a source of bioactive metabolites, in-depth studies of their morphology 
and physiology are necessary. 
From the available genetic and chemical data, the potential of halotolerant and halophilic 
myxobacteria as producers of chemically diverse secondary metabolites is out of 
question. Salimabromide 26 from E. salina is an outstanding example of such a molecule 
having a most unusual new carbon skeleton (100).  The number of molecules obtained 
so far, however, is very low (Table 8-1), especially when compared with the expected 
metabolites envisioned after bioinformatic analysis of the four available genomes of 
myxobacteria in the suborder Nannocystineae. All strains harbor at least 25 biosynthetic 
gene clusters (Chapter 4, table 4-1), most of them bearing no or very little homology to 
known biosynthetic genes. Compared to Myxococcus xanthus DK1622, the so far 
sequenced strains dedicate a similar or even larger portion of their genome of up to 10% 
to secondary metabolism. 
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Table 8-1 Metabolites reported to date from myxobacteria grouped into the suborder 
Nannocystineae and their bioactivities. 
Genus 
Classification 
according to 
salt 
requirements 
for growth 
Metabolites 
Metabolite [No] 
Bioactivity 
Nannocystis 
Terrestrial 
 
Nannocystin A 10 
 
10 
Antiproliferative activity, 
MDA-MB231 and its related 
drug resistant MDA-A1 (IC50 
= 6.5 and 12 nM 
respectively), HCT116 (IC50 
= 1.2 nM) and PC3 (IC50 = 
1.0 nM) 
 
Halotolerant 
 
 
 
 
 
 
 
 
Phenylnannolone A, 
B, C 11-13, 
Pyrronazol A, A2, B, 
C1, C2 14-18, 
Nannozinone A, B 21, 
22, 
Nannochelin A 23 
 
11 
Reversing drug-resistance of 
tumor cells 
21 
Mycobacterium diernhoferi, 
Candida albicans, Mucor 
hiemalis, MICs: 33.3 gmL-1 
in each case 
22 
Cytotoxicity, SKOV-3 IC50 = 
2.4 M, KB3-1 IC50 = 5.3 M 
and A431 IC50 = 8.45 M 
23 
Cytotoxicity, HUVEC and 
KB3-1 IC50 = 50 nM 
 
Haliangium 
Moderately 
halophilic 
Haliangicin 24 
Haliamide 25 
24 
Aspergillus niger, MIC: 12.5 
gmL-1, Phytophthora 
capsici, MIC: 0.4 gmL-1; 
25 
Cytotoxicity, HeLa-S3, IC50 
=12 M 
Enhygromyxa Halophilic Salimabromide 26 26, 27, 32 
Discussion and conclusions  
91 
 
Enhygrolide A, B 
27, 28 
Deoxyenhygrolide A, 
B 
29, 30 
Salimyxin A, B 
31, 32 
Enhygromic acid 
33 
Arthrobacter crystallopoietes,  
MICs: 16, 8 and 4 gmL-1 
respectively; 
33 
Cytotoxicity, melanoma B16, 
IC50=46 M; Bacillus subtillis, 
MIC: 8 gmL-1 
Myxobacterium 
SMH-27-4 
(Paraliomyxa) 
Slightly halophilic 
Miuraenamide A-F 
34-39 
34 
Trichophyton 
mentagrophytes, 
MIC: 12.5 gmL-1 
Plesiocystis Halophilic 
No metabolites 
described 
- 
Pseudenhygro-
myxa 
Halotolerant 
No metabolites 
described 
- 
 
These “cryptic” or “silent” gene clusters may be addressed with different strategies (138), 
e.g. the OSMAC (one strain, many compounds) approach (139) or co-culturing and 
elicitation techniques (140–142). Mass spectrometric analysis (143–146), dereplication 
procedures (80, 144), bioinformatic analysis and genetic experiments allow a direct 
connection of metabolites and gene clusters (78, 79, 145). On the other hand, recent 
advances in the direct cloning of gene clusters and their heterologous expression (147–
150) may enable researchers to select their “favorite” gene cluster and express and 
manipulate it in heterologous hosts for rational secondary metabolite discovery. These 
techniques offer the chance for an effective metabolomics-guided natural product and 
genome-mining platform. 
It can be concluded that the application of these promising state-of-the-art approaches 
to marine myxobacteria should expand our knowledge on novel secondary metabolites 
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in these organisms, and help to unveil systematically the chemistry encoded in their 
genomes. 
8.2. Discussion of metabolites isolated from the halophilic bacterium 
Labrenzia sp. strain 011 (Ostsee6) 
Apart from marine myxobacteria, different groups of sea-dwelling bacteria should be 
investigated as producers of secondary metabolites. A reason for this is provided by the 
findings derived from the investigations conducted on the halophilic bacterium Labrenzia 
sp. strain 011 (Ostsee6). Species of the genus Labrenzia were previously thought to be 
protective agents of the oyster Crassostrea virginica against the halophilic bacterium 
Pseudoroseovarius crassostreae, a frequent oyster pathogen (119). In this work, the 
antimicrobial compounds (1) and (2) isolated from L. aggregata sp. strain 011 (Ostsee6) 
were tested against P. crassostreae strain DSM 16950. Both compounds (1) and (2) 
revealed remarkable growth inhibition of the oyster pathogen in disc diffusion tests (1 
and 2, 5 mm diameter inhibition, 50 g/disc). The structures are shown in figure 8-1.  
 
cis - 4 - (2 - hexylcyclopropyl) - butanoic acid (1) 
  
cis - 2-(2 - hexylcyclopropyl) - acetic acid (2) 
Figure 8-1 Fatty acid-derivatives containing cyclopropyl groups were isolated from the 
halophilic bacterium Labrenzia sp. strain 011 (Ostsee6). Both compounds display 
remarkable antibacterial and antifungal activities. 
       
These results add up to the aforementioned notion that posed bacteria of the genus 
Labrenzia as biocontrol agents in the marine environment. Additionally, (1) and (2) 
exhibited antimicrobial properties against a range of fungi and bacteria, and compound 
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(2), interaction with the GPCR84 receptor in vitro. These aspects will be discussed in the 
upcoming sections. 
8.2.1. Hints on the biosynthetic origins of the cyclopropane-containing fatty 
acids derived from Labrenzia sp. strain 011 (Ostsee6) 
The biosynthetic origin of (1) and (2) remains unclear. However, studies on 
cyclopropane-containing fatty acids were performed earlier and found that these 
structures are typically produced in the cell membrane of an ample number of bacterial 
genera, hence functioning as structural components (151). The reaction involved is 
methylation of double bonds of unsaturated phospholipids via a fatty acid cyclopropane 
fatty acid synthase (CFAS)-mediated activity (CFAS, with S-adenosylmethionine 
(AdoMet) as a methyl donor (Figure 8-2)(151).  
 
 
Figure 8-2 Typical cyclopropanation mechanism observed in bacteria, e.g. Escherichia 
coli modified from (152). The substrates of the cyclopropane fatty acid synthase (CFAS) 
are usually unsaturated phospholipids. An alternative mechanism is observed in the 
genus Mycobacterium -efficient producers of cyclopropane fatty acids-, where the 
unsaturated alkyl chain is probably bound to an acyl carrier protein (152), suggesting the 
involvement of biosynthetic gene clusters in the production of this compund class.  
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Biebl et al. (118) conducted extensive profiling of structural fatty acids of various species 
comprised within the genus Labrenzia. Their work revealed unusual structures, 
predominantly 11-methyl 20:1ω6t, and 11-methyl 18:1ω6t, which reflect the capacity of 
these organisms to methylate unsaturated phospholipids. Additionally, genomic 
analyses conducted on the BRENDA system detected putative cyclopropane-fatty-acyl-
phospholipid synthase and class I SAM-dependent methyltransferases in annotated 
genomes of Labrenzia spp. (Data not shown). Therefore, one possible biosynthetic origin 
of (1) and (2) would be the cyclopropanation of unsaturated phospholipids in the 
membrane (Figure 8-2), subsequently cleaved to be released into the bacterial 
environment.  
Interestingly, CFAS are thought to be incapable to methylate regions close to the 
carboxylic end of the alkyl chains of phospholipids (151). Thus, it is worthwhile to 
investigate the biosynthetic origin of (1) and (2). 
8.2.2. Antimicrobial capacities of 1 and 2 
It is known that certain fatty acids are capable to exert notorious antimicrobial activities 
by inhibiting the synthesis of structural fatty acids in microorganisms or generating 
disturbances and instability in their cell membranes (153). Specifically, modified fatty 
acids with antifungal properties have been isolated from marine organisms in the past 
(154). The capacity of producing antimicrobial metabolites is a relevant feature for the 
hosts of Labrenzia, e.g. mollusks may harness to be protected against pathogens if 
Labrenzia metabolites (1) and (2) are produced in the natural environment. Experiments 
of Graça et al. (155) suggest that protection by Labrenzia is also provided to organisms 
like corals. They retrieved one organism of the genus Labrenzia from coral surfaces, 
whose extracts inhibited bacterial growth in vitro. 
It is thought that producers of antimicrobial compounds generate such substances to 
suppress competitors for nutrients and to kill or weaken living microbial preys of bacteria 
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that exhibit heterotrophic behavior, e.g. myxobacteria and Labrenzia spp.  (118, 36, 101, 
25, 156). 
Particularly striking in the present work was the efficient growth inhibition caused by (1) 
and (2) of the pathogen Pseudoroseovarius crassostreae DSM 16950T in disc diffusion 
tests, in which 50 g of (1) and (2) respectively produced a 5 mm inhibition zone, 
comparable to the 6 mm shown by 50 g of the positive control streptomycin. This fact 
strengthens the assumption of (118) regarding the protective role of bacteria of the genus 
Labrenzia against the roseovarius oyster disease. Probably, these antimicrobial 
compounds would provide protection against a wide range of microorganisms, 
considering the growth inhibition observed of test organisms of bacterial and fungal origin 
in disc diffusion testing.  
The factors triggering the production of antimicrobial CYPFAs should be a subject of 
deeper investigation, but microbial competition for nutrients could be a good reason to 
produce substances intended to overcome rivalry in the marine environment. This 
assumption makes sense if we consider that stress factors, e.g. nutrient deprivation, 
exposure to toxic entities and oxygen depletion stimulate the production of structural 
cyclopropanated fatty acids on the membranes of various bacterial genera under in vitro 
conditions (151, 157–159). This correlates with the fact that we observed the production 
of these compounds only after one week of cultivation. 
Additionally, it is reasonable to think that a few amount of gene clusters involved in 
secondary metabolism may suggest the performance of very specific tasks. This is 
reasonable if we consider the putative PKS, NRPS nature of the clusters found in our in 
silico screening, and knowing that molecules of this nature often display antimicrobial 
activities (66, 65, 67, 68). Bacteriocins, antimicrobial polypeptides, and proteins (160) 
are putatively produced by Labrenzia species according to the genome mining analyses. 
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It is worthwhile to keep in mind that these peptides may also mediate biological control 
by suppressing microbial diversification. 
To date, isolation of Labrenzia species has been reported in coastal areas with 
contrasting climate conditions: the Mediterranean region in Spain by (161), and German 
North Sea (this work). Furthermore, additional strains of Labrenzia aggregata and 
Labrenzia alexandrii were also isolated in our group from marine samples collected in 
the Peruvian Pacific Coast (data not shown). This suggests successful adaptability and 
presumably, a worldwide distribution.  
8.2.3. Effect of metabolites 1 and 2 on GPRC84 
Agonistic-mediated activation by medium-chain fatty acids (9-14 carbon chain length) as 
well as by the respective 2- or 3-hydroxy-fatty acids of GPCR84 lead to enhanced 
cytokine (IL-12 p40, IL-8, and TNF-α) production in myeloid cells (130, 128, 162). 
Additionally, the natural products embelin (3,3-diindolylmethane [DIM]), originally 
isolated from the plant Embelia ribes Rumb (Primulaceae), as well as the synthetic 
compound 6-octylaminouracil were found to act as GPR84 full agonists (163, 130). 
Surprisingly, recent works have proven embelin to ameliorate the symptoms of acute 
respiratory distress syndrome in murine models (163). This finds congruence with the 
demonstration that some agonistic agents are capable of exerting different effects 
according to the kind of agonism they exhibit, e.g. biased agonism or inverse agonism 
(164). Particularly, it has been observed that biased agonists are capable of inducing 
competitive- and noncompetitive-like antagonistic effects in the presence of agonists 
(165). Probably, inflammation promoters, e.g. decanoic acid (10C), dodecanoic acid 
(12C), and related compounds may promote inflammation by impeding the intracellular 
recruitment of cAMP and favoring the accumulation of -arrestins in accordance to our 
assays. 
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If the latter is true, it can be expected a GPR84-dependant anti-inflammatory effect 
mediated by the biased-agonist (2)  considering that selectively favors -arrestins 
recruitment (cAMP assay, EC50 > 100 M; -arrestin assay, EC50 = 0.114 ± 0.06 M), a 
phenomenon that leads to desensitization of agonist occupied-GPCR receptors (166, 
167). Furthermore, in vivo experiments have shown that accumulation of cAMP is 
involved in anti-inflammatory mechanisms in certain models of inflammation (168).  
Hence, it is likely to expect downregulation of GPR84, hence mitigation of inflammatory 
processes by (2) in vivo. This effect should not be surprising, since certain fatty acids (Ω-
monounsaturated) competitively inhibit the proinflammatory eicosanoid derivatives, e.g. 
leukotrienes, thus leading to mitigation of inflammatory response (169). Probably, 
cascarillic acid, analogous to (2) present in the tropical Caribbean shrub Croton eluteria, 
utilized in folk medicine to palliate the inflammatory symptoms of respiratory ailments, 
may be responsible for this putative medicinal effect (124–126). 
In spite of the evidence generated, further research is required to prove these 
hypotheses. Aspects to investigate future works are: i) evaluate the interaction of (2) with 
proinflammatory agonists of GPR84 and different proinflammatory receptors, ii) 
characterize ligand affinity of (2) towards different GPR-expressing tissues/cells in order 
to gain mechanistic insights, iii) assess anti-inflammatory activity using in vivo models, 
iiii) characterize the mechanisms of receptor attenuation (if any) and pathways activated 
by (2).  
The divergence among the in vitro biological effects of (1) and (2) may be explained by 
the relative position of the cyclopropyl structure relative to the carboxylic moiety of the 
hydrocarbon chains; also, the chain length seems to have an influence on the effects of 
the ligands according to the differences observed between C10 and C12. Lastly, the 
relative position of the ring in the hydrocarbon chain is decisive for the affinity of the 
compounds for the GPR84.  
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Although not fully understood, previous research suggests the involvement of the GPR84 
receptor in neuroinflammatory processes as well, e.g., multiple sclerosis and Alzheimer 
disease (170, 127). In this regard, the search for ligands affine to this receptor deserves 
particular attention in order to elucidate its function.   
8.3. Bacteria isolated from the German North Sea 
Bacteria isolated were capable of lysing microorganisms, probably due to the production 
of enzymes with the correspondent activity. This is a trait observed also in some other 
bacteria isolated from terrestrial and marine environments when exposed to alien 
organisms (125, 126). Bacterium Siel 3m was chosen for secondary metabolite isolation 
due to the growth inhibition shown in the domestic antimicrobial disc diffusion testing on 
a range of microorganisms, e.g. Bacillus megaterium DSM 32 (3 mm) and the fungus 
Microbotrium violaceum (2.5 mm). Additionally, the living organism displayed lytic activity 
against Saccharomyces sereviseae under co-culture conditions. To date, no metabolites 
responsible for any of the mentioned activities have been identified. Unfortunately, this 
organism lost its growth capacity under laboratory conditions in the development of this 
project, thus hindering assessment of further bioactivities. It would be desirable to 
reestablish the viability of this bacterium due to potential production of natural inhibitors. 
Extracts from this organism showed similar behavior of those of the bacterial mixture 
described in chapter 2 in terms of antimicrobial growth inhibition. Furthermore, 1H 
spectrum of crude extracts obtained by liquid-liquid extraction from liquid cultures 
showed signals similar to the ones produced by cyclopropyl groups of metabolites 
described in the previous chapter (Appendix, Figure 9-10). The activities displayed by 
the bacteria isolated is a reflection of the infinite possibilities of finding unknown 
organisms as well as novel compounds. It is especially notorious that conventional 
screening and isolation techniques remain to be useful tools to increase the stock of 
microorganisms with potential use for clinical purposes.   
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8.4. Closing remarks  
This work contributes to widening the reservoir of natural sources of bioactive 
compounds.  Previous reports had focused mainly on terrestrial organisms as a source 
of bioactive metabolites (171, 110, 49, 172, 173, 66, 72, 67, 68). However, marine-
derived organisms have been proven to be an underexplored source of interesting 
substances (101, 36, 174, 57, 60, 108). Furthermore, it was demonstrated that 
bioinformatics orient the classic experimental approaches in the isolation of metabolites 
of interest, or at least is helpful to determine whether it is worthwhile to put research 
efforts on a certain organism. Myxobacteria are excellent examples to illustrate the 
virtues of natural product research (66, 101, 77, 67, 68). These organisms are producers 
of compounds with most diverse bioactivities, and the possibilities to find novel structures 
is huge. To date, just a handful of these extraordinary bacteria has been isolated and the 
number of so far-isolated compounds in comparison to the ones putatively encoded in 
the genomes is minimum. Deeper investigations on the topic are available in recent 
works comprehending marine myxobacteria (36), but the low ratio isolated/encoded is 
also true for their terrestrial counterparts according to several bioinformatic analyses 
conducted in our lab and elsewhere. Factors hindering the isolation of new 
microorganism must be urgently overcome in order to accelerate the pace of discovery 
of novel drugs with the potential to become lead compounds.  
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10.1. A1. 16S rDNA Sequence of Labrenzia sp. strain 011 (Ostsee6) 
CGCATGCTCCGGCCGCCATGGCCGCGGGATTAAGGAGGTGATCCAGCCCCAGGTTCCCCTAGGGCTACCTTGTTA
CGACTTCACCCCAGTCGCTGAGCCTACCGTGGTCAGCTGCCTCCTTGCGGTTAGCGCACTGCCTTCGGGTAAACC
CAACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGTCATGCTGTTACGCGATTA
CTAGCGATTCCAACTTCATGCTCTCGAGTTGCAGAGAACAATCCGAACTGAGACGGCTTTTGGAGATTAGCTCCCT
CTCGCGAGTTCGCTGCCCACTGTCACCGCCATTGTAGCACGTGTGTAGCCCAGCCCGTAAGGGCCATGAGGACTT
GACGTCATCCCCACCTTCCTCTCGGCTTATCACCGGCAGTCCCCCTAGAGTGCCCAACTTAATGCTGGCAACTAAG
GGCGAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCAGCACCTG
TCCTGGCGTCCCCGAAGGGAACAATCGGTCTCCCGATCTAGCACCAAATGTCAAGGGCTGGTAAGGTTCTGCGCG
TTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAATCTTGCGACCG
TACTCCCCAGGCGGGAAGCTTAATGCGTTAGCTGCGCCACCAAATAGCATGCTACCTGACGGCTAGCTTCCATCGT
TTACGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGCACCTCAGCGTCAGTACCGAGCCA
GTGAGCCGCCTTCGCCACTGGTGTTCTTCCGAATATCTACGAATTTCGCCTCTACACTCGGAGTTCCACTCACCTCT
CTCGGTCTCAAGACTGACAGTATCAAAGGCAGTTCCGGGGTTGAGCCCCGGGATTTCACCCCTGACTGATCAGTC
CGCCTACGTGCGCTTTACGCCCAGTGATTCCGAACAACGCTAGCCCCCTTCGTATTACCGCGGCTGCTGGCACGA
AGTTAGCCGGGGCTTCTTCTGCGAGTAACGTCATTATCCTCCTCGCTGAAAGAGCTTTACAACCCTAGGGCCTTCA
TCACTCACGCGGCATGGCTGGATCAGGGTTGCCCCCATTGTCCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCT
GGGCCGTGTCTCAGTCCCAGTGTGGCTGATCATCCTCTCAGACCAGCTATGGATCGTCGCCTTGGTAGGCCATTA
CCCCACCAACTAGCTAATCCAACGCGGGCCCATCCTTAGGCGATAAATCTTCCCCCCATAGGGCACATACGGTATT
AGCAGTCGTTTCCAACTGTTGTTCCGTACCTAAAGGTAGGTTCCCACGCGTTACTCACCCGTCTGCCACTAACTCC
GAAGAGTTCGTTCGACTTGCATGTGTTAAGCCTGCCGCCAGCGTTCGTTCTGAGCCAGGATCAAACTCTAATCACT
AGTGCGGCCGCCTGCAGGTCGACCATATGGGAGAGCTCCCAACGCGTGA 
10.2. A2. 16s rDNA sequence of Siel 3m  
GCTCCCGGCCGCCATGGCCGCGGGATTAGAGTTTGATCCTGGCTCAGGATGAACGCTAGCGGCAGGCCTAATACA
TGCAAGTCGAGGGGCAGCATTCACTTCGGTGAGATGGCGACCGGCGAACGGGTGCGTAACGCGTATGCAACCTG
CCCCTTACCGGGGGATAGCCCAGAGAAATTTGGATTAACACCCCATAGCCCCGCGAGAAGGCATCTTCTTTCGGG
TAAATACTAAGGTAAGGGATGGGCATGCGTGCCATTAGTTAGTTGGCGGGGTAACGGCCCACCAAGGCAACGATG
GCTAGGGGTTCTGAGAGGATGATCCCCCACACTGGCACTGAGATACGGGCCAGACTCCTACGGGAGGCAGCAGT
AGGGAATATTGGTCAATGGGCGAGAGCCTGAACCAGCCATGCCGCGTGCAGGAAGACGGCCTTCTGGGTTGTAAA
CTGCTTTTACCAGGGAACAAAAGGCCCACGCGTGGGAGATTGCGTGTACCTGGGGGATAAGCACCGGCTAACTCC
GTGCCAGCAGCCGCGGTAANACGGAGGGTGCAAGCGTTGTCCGGATTTATTGGGTTTAAAGGGTGCGTAGGCGG
CCCGTTAAGTCAGGGGTGAAATCCCACAGCTCAACTGTGGAACTGCCCTTGATACTGGCGGGCTTGAGTACAGAC
GAGGTAGGCGGAATTTATGGTGTAGCGGTGAAATGCATAGATACCATAAAGAACACCGATAGCGAAGGCAGCTTAC
TGGACTGTAACTGACGCTGATGCACGAAAGCGTGGGTAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTA
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AACGATGATCACTCGATGTGTGCGACATTACTGTACGCGTCCAAGCGAAAGCGTTAAGTGATCCACCTGGGGAGTA
CGCCCGCAAGGGTGAAACTCAAAGGAATTGACGGGGGTCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGATGA
TACGCGAGGAACCTTACCTGGGCTAGAATGTGATTGCCATCCCCGGAGACGGGGAGTTCTTCGGACATGAAACAA
GGTGCTGCATGGCTGTCGTCAGCTCGTGCCGTGAGGTGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTACTGT
TAGTTGCCAGCACGTCAAGGTGGGGACTCTAACAGGACTGCCTGCGCAAGCAGAGAGGAAGGAGGGGACGACGT
CAAGTCATCATGGCCCTTACGCCCAGGGCTACACACGTGCTACAATGGGGGGTACAGCGGGTAGCTACCACGCAA
GTGGATGCCAATCTCAAAAAGCCCCTCTCAGTTCGGATCGTGGCCTGCAACTCGGCCACGTGAAGTTGGAATCGC
TAGTAATCGCGCATCAGCAATGGCGCGGTGAATACGTTCCCGGACCTTGTACACACCGCCCGTCAAGCCATGGAA
GTTGGGAGGACCTGAAGGCAGTAGCCTAGCGGCGCTGTTTAGGGTTATACCAGTAACTAGGGCTAAGTCGTAACA
AGGTAGCCGTACCGGAAGGTGGGGCTGGATCACCTCCTTAA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix  
10-III 
 
 
 
 
Figure 10-1 The figure shows the behavior of 1 and 2 during the HPLC run. The 
wavelength used was 230 nm. The retention times 17.76 min and 21.87 min indicate the 
signals of 2 and 1 respectively. The longer chain length of compound 1 determined a 
belayed retention time with respect to 2 in the reverse phase column. 
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Figure 10-2 The figure shows the UV spectrum of compound 1 at retention time 21.87 
min. The maximum absorbption for this molecule occurs at around 206 nm. 
 
 
Figure 10-3 The figure shows the UV spectrum of compound 2 at retention time 17.76 
min. The maximum absorpbtion for this molecule is around 200 nm. 
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       Figure 10-4 (+) HRMS spectrum of compound (1). The mass (m/z) is presented as  
       Na adduct (Calculated: 235.1629 / Measured: 235.1660). 
 
 
 
        Figure 10-5 (+) HRMS spectrum of compound (2). The mass (m/z) is presented as     
        Na adduct (Calculated: 207.1316 / Measured: 207.1308). 
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Figure 10-6 1H (300 MHz) Spectrum of compound 1 in CDCl3 
 
 
 
 
Figure 10-7 13C (300 MHz) Spectrum of compound 1 in CDCl3 
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Figure 10-8 13C - DEPT135 (300 MHz) Spectrum of compound 1 in CDCl3 
 
 
 
Figure 10-9 COSY (300 MHz) Spectrum of compound 1 in CDCl3 
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Figure 10-10 HSQC (300 MHz) Spectrum of compound 1 in CDCl3 
 
Figure 10-11 HMBC (300 MHz) Spectrum of compound 1 in CDCl3 
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Figure 10-12 1H (300 MHz) Spectrum of compound 2 in CDCl3 
 
 
 
Figure 10-13 13C (300 MHz) Spectrum of compound 2 in CDCl3 
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Figure 10-14 13C - DEPT135 (300 MHz) Spectrum of compound 2 in CDCl3 
 
 
Figure 10-15 COSY (300 MHz) Spectrum of compound 2 in CDCl3 
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Figure 10-16 HSQC (300 MHz) Spectrum of compound 2 in CDCl3 
 
Figure 10-17 NOESY (300 MHz) Spectrum of compound 2 in CDCl3 
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Figure 10-18 HMBC (300 MHz) Spectrum of compound 2 in CDCl3 
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Table 10-1 Comparison between the calculated  resonance values of 2 (300 MHz, 
CDCl3) and the cis-isomer of cascarillic acid as published by (126) (220 MHz, CDCl3). 
The measured and reference values are comparable, thus suggesting structural 
equivalence among 2 and cis-cascarillic acid.  
 
 
 
 
 
Position 
H (J in Hz) [ppm] 
calculated  
H [ppm] as published 
by (126) 
1 C - - 
2 CH2 
a: 2.42, dd (6.9, 16.0) 
b: 2.29, dd (7.8, 16.0) 
2.30, 2H-m 
3 CH2 1.26, m 1.18 – 1.46, 10H-m 
4 CH2 1.37, m 1.18 – 1.46, 10H-m 
5 CH2 1.29, m 1.18 – 1.46, 10H-m 
6 CH2 1.35, m 1.18 – 1.46, 10H-m 
7 CH2 1.29, m 1.18 – 1.46, 10H-m 
8 CH 0.81, m 0.66 – 0.88, 1H-m 
9 CH3 0.88, t (7.3) 0.89, 3H-t 
10 CH 1.10, m 1.00 – 1.18, 1H-m 
11 CH2 
at: 0.75, dq (8.4, 5.0) 
bc: -0.13, q (5.0) 
bc: -0.11, q 
Appendix  
10-XIV 
 
 
Figure 10-19 1H (300 MHz) Spectrum of crude extract from Siel 3m in CD3OD. The 
resonances from -0.4 ppm to 0.0 ppm are suggestive of protons conforming cycopropane 
groups (compare with Figures 9-6 and 
